US Pat. No. 9,219,998

PARTICIPANT GROUPING FOR ENHANCED INTERACTIVE EXPERIENCE

PRESIDENT AND FELLOWS OF ...

1. A system for grouping participants in an activity, the participants each having a handheld device, the system comprising:
a memory, the memory for storing participant records for one or more of the participants; and
a processor in operative communication with the memory, the processor being configured to:
determine one or more deterministic rules associated with one or more participant characteristics;
determine the one or more participant characteristics associated with the participants, the one or more participant characteristics
comprising:

at least one characteristic associated with one or more of the participants, and
an associated value of the at least one characteristic, wherein the associated value is identified from past performance between
the participants and one or more questions to identify the participants' knowledge of relevant subject matter;

determine a first group of participants associated with a first set of participant characteristics and associated values,
the first group including at least a first participant;

determine a second group of participants associated with a second set of participant characteristics and associated values,
the second group including at least the first participant;

computationally estimate a functional relationship of the first group of participants and the second group of participants
by comparing the first set of participant characteristics and associated values with the second set of participant characteristics
and associated values;

determine that the associated values for the first group of participants is greater than the associated values for the second
group of participants, wherein determining whether the associated values for the first group of participants is greater than
the associated values for the second group of participants is based in part on the one or more deterministic rules; and

communicate with the first group of participants in a communication through the participants' handheld devices, wherein:
the communication identifies at least the first participant to a recipient of the communication, and
the recipient of the communication is a second participant of the first group.

US Pat. No. 9,601,529

LIGHT ABSORPTION AND FILTERING PROPERTIES OF VERTICALLY ORIENTED SEMICONDUCTOR NANO WIRES

ZENA TECHNOLOGIES, INC., ...

1. A nanowire array, comprising a substrate and a plurality of nanowires extending essentially perpendicularly from the substrate,
wherein a ratio of a radius of the nanowires to a pitch of the nanowires is at most 0.5, wherein radii of the nanowires are
from 10 to 1000 nm; lengths of the nanowires are from 0.01 to 10 ?m.
US Pat. No. 9,434,985

METHODS OF IDENTIFYING INTERACTIONS BETWEEN GENOMIC LOCI

University of Massachuset...

1. A method for identifying interaction frequencies, comprising:
a) providing;
i) a nuclear matrix comprising a first genomic region and a second genomic region; and
ii) a junction marker labeled with an affinity marker for selective purification of a ligation product;
b) fragmenting said first genomic region and said second genomic region into a plurality of first genomic region fragments
and a plurality of second genomic region fragments;

c) ligating said junction marker between at least one of said first genomic region fragments and at least one of said second
genomic region fragments to create said ligation product;

d) purifying said ligation product with said affinity marker;
and
e) analyzing said ligation product under conditions such that a genomic interaction frequency for said ligation product is
identified.

US Pat. No. 9,238,206

CONTROL OF EMULSIONS, INCLUDING MULTIPLE EMULSIONS

President and Fellows of ...

1. A microfluidic device, comprising:
a first junction of microfluidic channels comprising at least first, second, and third microfluidic channels in fluidic communication,
the first junction in fluid communication at an interface with a second junction of microfluidic channels comprising at least
fourth, fifth, and sixth microfluidic channels in fluidic communication, each of the first, second, and third microfluidic
channels having a respective cross-sectional area at the first junction and each of the fourth, fifth, and sixth microfluidic
channels having a respective cross-sectional area at the second junction, wherein the interface has a cross-sectional area
smaller than the smallest cross-sectional areas of the fourth, fifth, and sixth microfluidic channels.

US Pat. No. 9,406,709

METHODS FOR FABRICATING AND USING NANOWIRES

PRESIDENT AND FELLOWS OF ...

1. A method for fabricating a nanowire comprising:
selecting a particular wavelength of electromagnetic radiation for absorption for a nanowire;
determining a diameter corresponding to the particular wavelength, wherein the nanowire with the determined diameter has an
absorption peak of electromagnetic radiation at the particular wavelength; and

fabricating the nanowire having the determined diameter.

US Pat. No. 9,052,448

TWO-DIMENSIONAL COUPLED RESONATOR OPTICAL WAVEGUIDE ARRANGEMENTS AND SYSTEMS, DEVICES, AND METHODS THEREOF

University of Maryland, C...

1. A topologically protected device comprising:
a two-dimensional array of coupled micro-resonator waveguides having four or more micro-resonators, said two-dimensional array
being of any geometry;

an input waveguide arranged adjacent to a first micro-resonator of the four or more micro-resonators such that photons in
said input waveguide are coupled to only said first micro-resonator and not any other micro-resonators of said four or more
micro-resonators; and

an output waveguide arranged adjacent to a second micro-resonator of said four or more micro-resonators, different from said
first micro-resonator, such that photons are coupled from only said second micro-resonator to said output waveguide and not
from any other micro-resonators of said four or more micro-resonators,

wherein said two-dimensional array is arranged so as to be operative to provide topological protection against any disorders
in said two-dimensional array,

the topological protection including providing an alternative pathway for photons traveling along a portion of the perimeter
of said two-dimensional array based on photonic edge states thereof such that the traveling photons bypass any disorder in
a photon path from said first micro-resonator to said second micro-resonator and such that the traveling photons coupled to
the output waveguide from the second micro-resonator are unaffected by any disorder in the two-dimensional array.

US Pat. No. 9,385,654

HIGH-PRECISION GHZ CLOCK GENERATION USING SPIN STATES IN DIAMOND

THE TRUSTEES OF COLUMBIA ...

1. A method for obtaining a frequency standard using the crystal field splitting frequency of at least one nitrogen vacancy
center in at least one diamond structure, comprising:
applying a microwave field to the at least one diamond structure, the microwave field having a frequency initially equal to
an initial frequency;

optically exciting the at least one diamond structure to create photoluminescence having a photoluminescent characteristic
based at least on the frequency of the microwave field;

detecting at least a first measurement of the photoluminescent characteristic at the initial frequency;
determining, based on the first measurement, a phase shift for the initial frequency from the constant crystal field splitting
frequency of the at least one diamond structure;

varying the frequency of the microwave field until a phase shift for the frequency of the microwave field from the constant
crystal field splitting frequency is below a predetermined threshold; and

using the frequency of the microwave field for which the phase shift is below the predetermined threshold as a frequency standard.
US Pat. No. 9,370,551

COMPOSITIONS AND METHODS OF TREATING HEAD AND NECK CANCER

The Broad Institute, Inc....

1. A method of altering expression of a genomic locus of interest in a mammalian cell,
comprising contacting the genomic locus with a non-naturally occurring or engineered composition comprising a deoxyribonucleic
acid (DNA) binding polypeptide comprising:

(a) a N-terminal capping region
(b) a DNA binding domain comprising at least five or more TALE monomers and at least one or more half-monomers specifically
ordered to target the genomic locus of interest, and

(c) a C-terminal capping region
wherein (a), (b) and (c) are arranged in a predetermined N-terminus to C-terminus orientation,
wherein the polypeptide includes at least one or more effector domains, and
wherein the polypeptide is encoded by and translated from a codon optimized nucleic acid molecule so that the polypeptide
preferentially binds to DNA of the genomic locus; and

wherein the genomic locus of interest is associated with TP63, CCND1, CCNE1, YAP1, HRAS, PIK3CA, PIK3CG, NOTCH1, NOTCH 2,
NOTCH 3, IRF6, CDKN2A, TP53, CASP8, PTEN, FAT1, RIPK4, EZH1, EZH2, MED1, MLL2, CDH1, FBXW7, PCLO, RIMS2, RB1, NSD1 or NFE2L2.

US Pat. No. 9,074,009

STABILIZED MAML PEPTIDES AND USES THEREOF

Dana-Farber Cancer Instit...

1. A modified polypeptide of Formula (I),

wherein:
each R1 and R2 are independently H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclylalkyl;

each R3 is independently alkyl, alkenyl, alkynyl or [R4—K—R4]n; each of which is substituted with 0-6 R5;

each R4 is independently alkyl, alkenyl, or alkynyl;

each R5 is independently halo, alkyl, OR6, N(R6)2, SR6, SOR6, SO2R6, CO2R6, R6, a fluorescent moiety, or a radioisotope;

each K is independently O, S, SO, SO2, CO, CO2, CONR6, or


each R6 is independently H, alkyl, or a therapeutic agent;

n is an integer from 1-4;
x is 3, 4 or 6;
y and w are independently an integer between 0 and 15;
z is 1; and
each Xaa is independently an amino acid;
wherein the modified polypeptide consists of 8-20 contiguous amino acids of SEQ ID NO:1 and: (a) within a sequence of 8 contiguous
amino acids the side chains of at least one pair of amino acids separated by 3, 4 or 6 amino acids are replaced by the linking
group R3 which connects the alpha carbons of the pair of amino acids as depicted in Formula (I); and (b) the alpha carbon of the first
of the pair of amino acids is substituted with R1 as depicted in Formula (I) and the alpha carbon of the second of the pair of amino acids is substituted with R2 as depicted in Formula (I); wherein and N or C can be substituted by PEG, spermine, or a carbohydrate.

US Pat. No. 9,381,235

PROGRAMMING OF CELLS FOR TOLEROGENIC THERAPIES

President and Fellows of ...

1. A method of reducing the severity of an autoimmune disorder, comprising identifying a subject suffering from an autoimmune
disorder and administering to said subject a scaffold composition comprising an antigen, a recruitment composition, and a
tolerogen,
wherein said antigen is derived from a cell to which a pathologic autoimmune response associated with said disorder is directed;
wherein said tolerogen induces immune tolerance or a reduction in an immune response;
wherein said tolerogen is selected from the group consisting of retinoic acid, rapamycin, aspirin, and vasoactive intestinal
peptide; and

wherein the scaffold composition does not comprise IL-10, dexamethasone, vitamin D, or TGF-beta.
US Pat. No. 9,308,280

TARGETING OF ANTIGEN PRESENTING CELLS WITH IMMUNONANOTHERAPEUTICS

Massachusetts Institute o...

1. A composition comprising:
(a) polymeric particles formed from the self-assembly of a mixture of amphiphilic (hydrophobic-hydrophilic) polymers and amphiphilic
polymers having at least one moiety bound to the hydrophilic ends of the amphiphilic polymers;

(b) a B cell or T cell antigen;
(c) an immunostimulatory agent to promote tolerance to the antigen; and
(d) a pharmaceutically acceptable excipient.
US Pat. No. 9,233,072

ADJUVANT INCORPORATION IN IMMUNONANOTHERAPEUTICS

Massachusetts Institute o...

1. A composition comprising:
(1) polymeric synthetic nanocarriers formed from the self-assembly of a mixture of amphiphilic polymers comprising a hydrophilic
and a hydrophobic polymer, and amphiphilic polymers having a moiety attached thereto prior to self-assembly into nanocarriers

wherein the moiety is a targeting moiety that binds markers on dendritic cells or subcapsular sinus macrophages or is an immunostimulatory
agent for dendritic cells or subcapsular sinus macrophages; and

(2) a pharmaceutically acceptable excipient.

US Pat. No. 9,108,955

HETEROCYCLIC INHIBITORS OF NECROPTOSIS

President and Fellows of ...

1. The compound

US Pat. No. 9,173,910

COMPOSITIONS OF MICROBIOTA AND METHODS RELATED THERETO

The General Hospital Corp...

1. A method of altering relative abundance of microbiota in a subject comprising administering to the subject an effective
dose of a composition consisting essentially of substantially purified Verrucomicrobia; wherein the subject has a disorder
selected from the group consisting of: obesity, metabolic syndrome, insulin deficiency, insulin-resistance related disorders,
glucose intolerance, diabetes, non-alcoholic fatty liver, and abnormal lipid metabolism.

US Pat. No. 9,077,975

SUB-DIFFRACTION LIMIT IMAGE RESOLUTION IN THREE DIMENSIONS

President and Fellows of ...

1. A method, comprising:
providing a plurality of entities able to emit light;
activating a fraction of the plurality of entities to emit light;
determining the emitted light;
deactivating the activated fraction of the plurality of entities; and
repeating the acts of activating and deactivating the plurality of entities to determine x, y, and z positions of the plurality
of entities, wherein the x, y, and z positions of the plurality of entities are 3-D spatial coordinates and are each determined
to a precision better than the wavelength of the light emitted by some of the plurality of entities, and wherein the z positions
of the plurality of entities are determined using astigmatism imaging.

US Pat. No. 9,475,013

DROPLET FORMATION USING FLUID BREAKUP

President and Fellows of ...

1. A method of producing droplets, comprising:
providing a first continuous fluid stream comprising a first fluid, and a second continuous fluid stream comprising a second
fluid and a plurality of insertable microfluidic droplets comprising a third fluid, the plurality of insertable droplets contained
within the second fluid; and

inserting the plurality of insertable droplets into the first continuous fluid stream at a junction to cause the first continuous
fluid stream to break up into discrete droplets of the first fluid, wherein the plurality of the insertable droplets and the
discrete droplets exit the junction after the insertion of the plurality of the insertable droplets;

wherein the first continuous fluid stream comprising the first fluid is a fluid jet.

US Pat. No. 9,434,686

DEACETYLASE INHIBITORS AND USES THEREOF

President and Fellows of ...

1. A method of treating a histone deacetylase-associated cancer in a subject, the method comprising administering to the subject
a therapeutically effective amount of a compound of formula (I):

or a pharmaceutically acceptable form thereof;
wherein:
n is an integer between 1 and 10, inclusive;
m is an integer between 0 and 5, inclusive;
k is an integer between 0 and 5, inclusive;
p is an integer between 0 and 5, inclusive;
R2 is an optionally substituted acyl moiety;

R3 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic,
substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched
acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl;
—ORC; —C(?O)RC; —CO2RC; —CN; —SCN; —SRC; —SORC; —SO2RC; —NO2; —N(RC)2; —NHC(?O)RC; or —C(RC)3; wherein each occurrence of RC is independently hydrogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety; an aryl moiety;
a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino; alkylamino; dialkylamino; heteroaryloxy; or a heteroarylthio
moiety;

R4 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic,
substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched
acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl;
—ORD; —C(?O)RD; —CO2RD; —CN; —SCN; —SRD; —SORD; —SO2RD; —NO2; —N(RD)2; —NHC(?O)RD; or —C(RD)3; wherein each occurrence of RD is independently hydrogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety; an aryl moiety;
a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino; alkylamino; dialkylamino; heteroaryloxy; or a heteroarylthio
moiety;

R5 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic,
substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched
acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl;
—ORE; —C(?O)RE; —CO2RE; —CN; —SCN; —SRE; —SORE; —SO2RE; —NO2; —N(RE)2; —NHC(?O)RE; or —C(RE)3; wherein each occurrence of RE is independently hydrogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety; an aryl moiety;
a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino; alkylamino; dialkylamino; heteroaryloxy; or a heteroarylthio
moiety; and

wherein the histone deacetylase-associated cancer is selected from the group consisting of leukemia, multiple myeloma, lymphoma,
and skin cancer.

US Pat. No. 9,234,885

METHODS AND ASSAYS FOR TREATING FILOVIRIDAE INFECTIONS

Albert Einstein College o...

1. A method for treating a subject infected with an ebolavirus or a marburgvirus or for preventing an infection with an ebolavirus
or a marburgvirus in a subject exposed to an ebolavirus or a marburgvirus comprising administering to the subject an agent
that inhibits Niemann-Pick C1 (NPC1) in an amount effective to treat and/or prevent infection with an ebolavirus or a marburgvirus.
US Pat. No. 9,163,086

METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE AND PATHOGENIC DISEASES

PRESIDENT AND FELLOWS OF ...

1. An antibody or functional derivative thereof comprising a light chain variable domain and a heavy chain variable domain,
wherein the light chain variable domain comprises a complementarity determining region (CDRL1) comprising the sequence of
GASQSVSSSYLA (SEQ ID NO:11), a CDRL2 comprising the sequence of ASSRATGIPD (SEQ ID NO:12), and a CDRL3 comprising the sequence
of YGSSPPVT (SEQ ID NO:13); and wherein the heavy chain variable domain comprises a CDRH1 comprising the sequence of SYDIN
(SEQ ID NO:14), a CDRH2 comprising the sequence of WMNPNSGNTGYAQKFQG (SEQ ID NO:15), and a CDRH3 comprising the sequence of
GKGSGYYNY (SEQ ID NO:16).

US Pat. No. 9,056,299

SCALE-UP OF FLOW-FOCUSING MICROFLUIDIC DEVICES

President and Fellows of ...

1. A system for forming droplets in microfluidic channels in parallel, comprising:
a distribution channel having an inlet fluidly connected to a plurality of microfluidic subject fluid outlets arranged parallel
to each other, each outlet defining a portion of a microfluidic interconnected region in fluid communication with at least
one dispersing fluid channel fluidly connected to a source of a dispersing fluid; and

at least one intermediate fluid channel fluidly connecting to the interconnected region and subject fluid outlets.

US Pat. No. 9,340,505

TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF

University of Massachuset...

1. A method for inhibiting activity of a type III secretion system of a bacterium, comprising contacting a bacterium having
a type III secretion system with an effective amount of at least one compound that inhibits a type III secretion system, wherein
the at least one compound is a compound of the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
R9 is selected from the group consisting of:
—(C1-C5)alkyl,
—(C1-C5)alkyl-CO2H, and


wherein R12 is -halogen,
R10 is selected from the group consisting of:
-hydrogen,
—(C1-C6)alkyl, and
—O—(C1-C6)alkyl;
R11 is selected from the group consisting of:

wherein R13 is -hydrogen or —(C1-C6)alkyl.

US Pat. No. 9,056,289

DROPLET CREATION TECHNIQUES

President and Fellows of ...

1. A method for forming a plurality of droplets, comprising:
providing an emulsion comprising a plurality of droplets, at least some of the droplets comprising a first fluid the droplets
substantially surrounded by a second fluid; and

passing the emulsion droplets through an intersection in a microfluidic channel to form a plurality of divided droplets, wherein
the intersection comprises at least two intersecting channels containing an entering third fluid intersecting the microfluidic
channel at the intersection.

US Pat. No. 9,186,643

IN VITRO EVOLUTION IN MICROFLUIDIC SYSTEMS

Medical Research Council,...

1. A method for producing an encapsulated gene product, comprising the steps of:
(a) providing within a first microcapsule within a microfluidic channel a first genetic element encoding a first gene product,
the microcapsule comprising an aqueous fluid substantially surrounded by an immiscible fluorinated oil including a fluorinated
polymer surfactant, wherein the microcapsule is able to contact without fusing with another microcapsule due to presence of
the surfactant;

(b) providing conditions within the first microcapsule suitable for the expression of the first genetic element to form its
first gene product;

(c) introducing at least one of a first microbead to the first microcapsule, wherein the first microbead is either encapsulated
within the first microcapsule prior to the expression of the first genetic element or is encapsulated within the first microcapsule
subsequent to the expression of the first genetic element; and

(d) complexing the first gene product with at least one of the plurality of first microbeads via a capture moiety on the first
microbead.

US Pat. No. 9,297,005

HARNESSING CELL DYNAMICS TO ENGINEER MATERIALS

President and Fellows of ...

1. A method of inducing differentiation of a population of stem cells into an osteogenic lineage comprising
contacting said stem cells with a 3-dimensional material, wherein the 3-dimensional material comprises alginate of a stiffness
in the range of 22-45 kPa, and a density of adhesion molecules presented by the alginate of 150 nmol/L to 200 ?mol/L, wherein
said stem cells are encapsulated in the 3-dimensional material,

wherein said density and said stiffness induce the formation of sufficient bonds between said stem cells and said adhesion
molecules, and wherein the number of such bonds formed between said stem cells and said adhesion molecules determines a cell
type into which said stem cells differentiate; and

allowing said stem cells to bind to, and mechanically reorganize, said adhesion molecules, thereby inducing differentiation
of said stem cells into an osteogenic lineage.

US Pat. No. 9,248,185

METHODS OF INCREASING SATELLITE CELL PROLIFERATION

President and Fellows of ...

1. A method of increasing satellite cell proliferation in a subject in need thereof, the method comprising contacting a satellite
cell of the subject with a compound and thereby increasing satellite cell proliferation, wherein the compound is CEP-701.
US Pat. No. 9,079,952

METHOD FOR DELIVERING AGENTS INTO CELLS USING BACTERIAL TOXINS

President and Fellows of ...

1. A method for delivering a bioactive moiety comprising at least one non-natural component into a cell cytosol of an eukaryotic
cell comprising contacting the cell with (a) a fusion molecule comprising the bioactive moiety attached to an A component
of a bacterial toxin, a functional wild-type or modified fragment thereof, or an A component surrogate or mimetic; and (b)
a corresponding B component of the bacterial toxin or a functional fragment thereof, wherein the non-natural component is
selected from the group consisting of a peptide or protein comprising one or more D-amino acids.
US Pat. No. 9,068,179

METHODS FOR CORRECTING PRESENILIN POINT MUTATIONS

President and Fellows of ...

1. A method of editing a nucleic acid molecule encoding a Presenilin1 (PSEN1) protein, the method comprising contacting the
nucleic acid molecule with
(a) a fusion protein comprising a nuclease-inactive Cas9 domain and a deaminase domain; and
(b) a single guide RNA (sgRNA) targeting the fusion protein of (a) to the PSEN1-encoding nucleic acid molecule;
wherein the nucleic acid molecule comprises a T>C and/or an A>G point mutation in the PSEN1-encoding nucleic acid molecule
as compared to a wild-type PSEN1-encoding nucleic acid molecule,

and wherein the PSEN1-encoding nucleic acid molecule is contacted with the fusion protein and the sgRNA in an amount effective
and under conditions suitable for the deamination of the mutant C or G nucleotide base.

US Pat. No. 9,365,493

SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF

President and Fellows of ...

1. A method of synthesizing a compound of formula:
or salt, isomer, or tautomer thereof;wherein:
R1 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic,
substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted acyl; substituted or unsubstituted
aryl; substituted or unsubstituted heteroaryl; —ORA; —C(?O)RA; —CO2RA; —CN; —SCN; —SRA; —SORA; —SO2RA; —NO2; —N(RA)2; —NHC(O)RA; or —C(RA)3; wherein each occurrence of RA is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio,
arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

R2 is hydrogen;

R3 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic,
substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted acyl; substituted or unsubstituted
aryl; substituted or unsubstituted heteroaryl; —ORC; —C(?O)RC; —CO2RC; —CN; —SCN; —SRC; —SORC; —SO2RC; —NO2; —N(RC)2; —NHC(O)RC; or —C(RC)3; wherein each occurrence of RC is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio,
arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

R4 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic,
substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted acyl; substituted or unsubstituted
aryl; substituted or unsubstituted heteroaryl; —ORD; —C(?O)RD; —CO2RD; —CN; —SCN; —SRD; —SORD; —SO2RD; —NO2; —N(RD)2; —NHC(O)RD; or —C(RD)3; wherein each occurrence of RD is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio,
arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

R5 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic,
substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted acyl; substituted or unsubstituted
aryl; substituted or unsubstituted heteroaryl; —ORE; —CN; —SCN; —SRE; or —N(RE)2; wherein each occurrence of RE is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio,
arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

each occurrence of R7 is independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic
or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted acyl; substituted
or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORG; —C(?O)RG; —CO2RG; —CN; —SCN; —SRG; —SORG; —SO2RG; —NO2; —N(RG)2; —NHC(O)RG; or —C(RG)3; wherein each occurrence of RG is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, heteroaryl, alkoxy, aryloxy, alkylthio,
arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio; and

n is 0 or an integer in the range of 1 to 3, inclusive;the method comprising:
reacting an anion of a toluate, wherein the toluate is of formula:
wherein the anion is formed by deprotonation of a toluate under basic conditions, andwherein:
R9 is —ORI, —CN, —SCN, —SRI, or —N(RI)2; and each RI is independently hydrogen; a protecting group; a cyclic or acyclic, substituted or unsubstituted aliphatic; a cyclic or acyclic,
substituted or unsubstituted heteroaliphatic; a substituted or unsubstituted aryl; or a substituted or unsubstituted heteroaryl;
and

P is hydrogen, lower (C1-C6) alkyl, acyl, or a protecting group;
with an enone of formula:
or a salt, isomer, or tautomer thereof;wherein:
R6 is hydrogen; and

each P? is independently hydrogen or a protecting group;to provide a compound of formula:
or a salt, isomer, or tautomer thereof.

US Pat. No. 9,540,317

CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF

President and Fellows of ...

1. A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
R is a cyclic or acyclic, substituted or unsubstituted aliphatic moiety; a cyclic or acyclic, substituted or unsubstituted
heteroaliphatic moiety; a substituted or unsubstituted aryl moiety; or a substituted or unsubstituted heteroaryl moiety; and

each occurrence of R? is independently hydrogen, halogen, or C1-6alkyl.

US Pat. No. 9,457,080

METHODS AND COMPOSITIONS FOR THE TREATMENT OF PERSISTENT INFECTIONS AND CANCER BY INHIBITING THE PROGRAMMED CELL DEATH 1 (PD-1) PATHWAY

Emory University, Atlant...

1. A method of increasing cytotoxic activity of anergic T cells in a subject having a lymphoproliferative cancer, comprising
administering to the subject having the lymphoproliferative cancer an effective amount of an agent that reduces the activity
or expression of a Programmed Cell Death (PD)-1 polypeptide, wherein the agent is an anti-Programmed Cell Death Ligand (PD-L)1
antibody,

thereby increasing the cytotoxic activity of anergic T cells in the subject with the lymphoproliferative cancer, wherein the
lymphoproliferative cancer is a Hodgkin's lymphoma.

US Pat. No. 9,371,552

NUCLEIC ACID NANOTUBE LIQUID CRYSTALS

Dana-Farber Cancer Instit...

1. A composition comprising nucleic acid nanotubes, each nanotube having a nanotube length, each nanotube formed from a single-stranded
scaffold nucleic acid molecule and a plurality of staple oligonucleotides together forming a number of double-stranded nucleic
acid helices joined by the single-stranded scaffold nucleic acid molecule, the nanotube length being the length of the single-stranded
scaffold nucleic acid molecule divided by the number of double stranded nucleic acid helices comprising each nanotube, and
wherein the length of the nucleic acid helices varies by no more than 20% of an average length of the helices, and wherein
each of the nanotubes comprises at least three adjacent double-stranded helices.

US Pat. No. 9,180,114

NEURODEGENERATIVE DISEASES AND METHODS OF MODELING

PRESIDENT AND FELLOWS OF ...

1. A method of treating motor neuron disease, the method comprising administering an inhibitor of a prostaglandin D2 DP1 receptor
comprising the compound of formula (II)

to a subject in need thereof, wherein the inhibitor inhibits expression or activity the prostaglandin D2 DP1 receptor, wherein
the motor neuron disease is amyotrophic lateral sclerosis (ALS), and wherein: R1 is H or C1-C6 alkyl; R2 is aryl or heteroaryl, each of which can be optionally substituted; R3 and R4 are each independently is halo, —CF3, —CN, —NO2, —S(?O)alkyl, —SO2alkyl, C1-C6 alkyl; —C(O)alkyl, —CH(OH)alkyl; and m is 1, 2 or 3.

US Pat. No. 9,464,115

STABILIZED ALPHA HELICAL PEPTIDES AND USES THEREOF

DANA-FARBER CANCER INSTIT...

1. A cell-penetrable cross-linked polypeptide of Formula (I):

wherein:
each R1 and R2 are independently H, C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclylalkyl; wherein at least either R1 or R2 is C1-C20 alkyl, C2-C20 alkenyl, C2-C20 alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclylalkyl;

R3 is a covalent crosslink spanning from one to two turns of an alpha helix;

x is an integer selected from 2 to 6;
each y is independently an integer from 0-100;
z is an integer from 1-10; and
each Xaa is independently an amino acid,
wherein the polypeptide has a substantially alpha helical secondary structure in aqueous solution and penetrates a cell membrane.

US Pat. No. 9,421,211

N,N?-DIARYLUREA COMPOUNDS AND N,N?-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION

President and Fellows of ...

1. A method for inhibiting the proliferation of human cancer cells comprising contacting the cells selected from the group
consisting of squamous carcinoma cells, human breast cancer cells, human melanoma cells, human lung cancer cells and human
prostate cancer cells, with compound

US Pat. No. 9,370,558

CONTROLLED DELIVERY OF TLR AGONISTS IN STRUCTURAL POLYMERIC DEVICES

President and Fellows of ...

2. A method for eliciting an anti-tumor immune response, comprising contacting or implanting into a subject a device comprising
a polymeric structure composition, a tumor antigen, a TLR3 agonist and a TLR9 agonist, wherein said anti-tumor immune response
comprises activation of a CD8+ dendritic cell, a plasmacytoid dendritic cell, or a CD141+ dendritic cell, wherein said TLR3
agonist comprises condensed poly I:C cationic nanoparticles, and wherein said tumor comprises a solid tumor, said condensed
poly I:C cationic nanoparticles being formed by mixing said poly I:C with a polycation comprising positively charged amine
groups at a charge ratio resulting in positively charged condensates and an average particle size of 98-545 nm.

US Pat. No. 9,304,067

METHODS, APPARATUS AND SYSTEMS FOR PRODUCTION, COLLECTION, HANDLING, AND IMAGING OF TISSUE SECTIONS

President and Fellows of ...

1. A system for processing a tissue sample, the system comprising:
a cutting portion including:
a cutting surface for contacting the tissue sample so as to liberate a thin tissue section that includes at least a portion
of the tissue sample, and

a water bath constructed and arranged to contain water having a surface for supporting the thin tissue section; and
a collecting portion including:
a conductive support tape for collecting the thin tissue section from the surface of the water on to the support tape, wherein
the support tape is adapted for electron microscopy, and

a conveyor device upon which the support tape is disposed for automatically guiding the support tape and the thin tissue section
toward a collection region;

wherein the water disposed within the water bath provides a sole region of contact between the cutting portion and the collecting
portion.

US Pat. No. 9,273,099

STABILIZED ALPHA HELICAL PEPTIDES AND USES THEREOF

PRESIDENT AND FELLOWS OF ...

1. A method for promoting apoptosis of a neoplastic cell in a subject in need thereof, comprising administering to the subject
a therapeutically effective amount of a pharmaceutical composition comprising a cross-linked polypeptide and a pharmaceutically
acceptable carrier, wherein the cross-linked polypeptide is derived from a pro-apoptotic protein involved in a cellular apoptotic
pathway,
wherein the cross-linked polypeptide has the Formula (I): Formula (I)

wherein:
each R1 and R2 are independently H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclylalkyl;

R3 is alkyl, alkenyl, alkynyl, [R4—K—R4]n, or a naturally occurring amino acid side chain;

wherein R3 is substituted with 0-6R5;

R4 is alkyl, alkenyl, or alkynyl;

R5 is halo, alkyl, OR6, N(R6)2, SR6, SOR6, SO2R6, CO2R6, R6, a fluorescent moiety, or a radioisotope;

K is O, S, SO, SO2, CO, CO2, CONR6, or


R6 is H, alkyl, or a therapeutic agent;

n is an integer from 1-4;
x is an integer selected from 2-10;
each y is independently an integer from 0-100;
z is an integer from 1-10; and
each Xaa is independently an amino acid;
wherein the polypeptide has a substantially alpha helical secondary structure in aqueous solution.
US Pat. No. 9,176,105

DENSITY-BASED SEPARATION OF BIOLOGICAL ANALYTES USING MULTIPHASE SYSTEMS

President and Fellows of ...

1. A method of analyzing or separating a sample comprising one or more biological analytes of interest using a multi-phase
system, comprising:
a) providing a multi-phase system comprising two or more phase-separated solutions having a stable interface between adjacent
phases, wherein

the two or more phase-separated solutions comprise
a first phase solution comprising a first phase component predominantly residing in the first phase solution; and
a second phase solution adjacent to the first phase solution and comprising a second phase component predominantly residing
in the second phase solution, said second phase component different from the first phase component;

wherein the first and second phase solutions have a common solvent and each of the first and second phase components is selected
from the group consisting of a polymer, a surfactant and combinations thereof, wherein at least one of the first and second
phase components comprises a polymer;

each said phase has an upper and a lower phase boundary; and
each of the two or more phases has a different density and the phases, taken together, represent a density gradient;
b) introducing a biological sample comprising one or more biological analytes of interest without disrupting the phase-separated
solution; and

c) allowing the biological analyte to migrate to a location in the multi-phase system that is characteristic of its density,
wherein during migration the analyte contacts one or more of the two or more phases sequentially such that the analyte's final
position in the system is not determined predominantly by partitioning.

US Pat. No. 9,107,933

COMPOSITIONS AND METHODS OF TARGETING APOLIPOPROTEIN B FOR THE REDUCTION OF APOLIPOPROTEIN C-III

Isis Pharmaceuticals, Inc...

1. A method of lowering plasma apolipoprotein C-III levels in a human subject, comprising:
selecting a human subject with elevated apolipoprotein C-III levels or a condition associated with apolipoprotein C-III; and
administering to said human subject a therapeutically effective amount of a compound comprising a modified oligonucleotide
having 12-30 linked nucleosides, or a salt thereof,

wherein said modified oligonucleotide is 100% complementary to a nucleic acid encoding human apolipoprotein B, and whereby
plasma apolipoprotein C-III levels in said human subject are lowered.

US Pat. No. 9,073,829

SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO

President and Fellows of ...

1. A compound of formula:
or a pharmaceutically acceptable salt thereof;wherein:
---- represents a single or double bond;
R1 and R2 are each independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched
or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORA; —CH2ORA; —CH2RA; —CH2N(RA)2; —C(?O)RA; —CO2RA; —CN; —SCN; —SRA; —SORA; —SO2RA; —N3; —NO2; —N(RA)2; —NHC(O)RA; —NHSO2RA; or —C(RA)3; wherein each occurrence of RA is independently hydrogen, halogen, azido, a protecting group, aliphatic, heteroaliphatic, haloaliphatic, acyl, aryl, heteroaryl,
alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio; or R1 and R2 are taken together to form ?O or ?C(RA)2;

R3 and R4 are each independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched
or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORB; —CH2ORB; —CH2RB; CH2N(RB)2; —C(?O)RB; —CO2RB; —CN; —SCN; —SRB; —SORB; —SO2RB; —N3; —NO2; —N(RB)2; —NHC(O)RB; —NHSO2RB; or —C(RB)3; wherein each occurrence of RB is independently hydrogen, halogen, azido, a protecting group, aliphatic, heteroaliphatic, haloaliphatic, acyl, aryl, heteroaryl,
alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio; or R3 and R4 are taken together to form ?O or ?C(RB)2;

R5, R9, and R11 are each independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic;
cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched
or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORC; —CH2ORC; —CH2RC; —CH2N(RC)2; —C(?O)RC; —CO2RC; —CN; —SCN; —SRC; —SORC; —SO2RC; —N3; —NO2; —N(RC)2; —NHC(O)RC; —NHSO2RC; or —C(RC)3;

each R7 is independently halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic,
substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched
acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORC; —CH2ORC; —CH2RC; —CH2N(RC)2; —C(?O)RC; —CO2RC; —CN; —SCN; —SRC; —SORC; —SO2RC; —N3; —NO2; —N(RC)2; —NHC(O)RC; —NHSO2RC; or —C(RC)3;

R10 is halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted
or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted
or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORC; —CH2ORC; —CH2RC; —CH2N(RC)2; —C(?O)RC; —CO2RC; —CN; —SCN; —SRC; —SORC; —SO2RC; —N3; —NO2; —N(RC)2; —NHC(O)RC; —NHSO2RC; or —C(RC)3;

each occurrence of RC is independently hydrogen, halogen, azido, a protecting group, aliphatic, heteroaliphatic, haloaliphatic, acyl, aryl, heteroaryl,
alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio;

R6 and R8 are absent if the dashed line between the carbon atoms which R6 and R8 are attached to represents a bond, or are each independently hydrogen, halogen, substituted or unsubstituted aliphatic, substituted
or unsubstituted heteroaliphatic, haloaliphatic, substituted or unsubstituted alkoxy, —OH, —CN, —SCN, —SH, alkylthio, —N3; —NO2, amino, alkylamino, or dialkylamino;

each RP is independently hydrogen, substituted or unsubstituted aliphatic, substituted or unsubstituted heteroaliphatic, haloaliphatic,
a protecting group, substituted or unsubstituted acyl, substituted or unsubstituted aryl, or substituted or unsubstituted
heteroaryl; and

n is an integer in the range of 0 to 8, inclusive.
US Pat. No. 9,057,734

OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL

President and Fellows of ...

1. A method for measuring membrane potential in a cell expressing a nucleic acid encoding a microbial rhodopsin protein, the
method comprising the steps of:
a. exciting, in vitro, at least one cell comprising a nucleic acid encoding a microbial rhodopsin protein with light of at
least one wave length; and

b. detecting, in vitro, at least one optical signal from the at least one cell, wherein the level of fluorescence emitted
by the at least one cell compared to a reference is indicative of the membrane potential of the cell.

US Pat. No. 9,199,923

HISTONE DEACETYLASE INHIBITORS

President and Fellows of ...

1. A method of inhibiting histone deacetylase, the method comprising steps of:contacting a histone deacetylase with a compound of the formula (Ib):
or a pharmaceutically acceptable salt thereof, wherein
n is 5, 6, or 7;
m is an integer from 1 to 5;
each R1 is independently hydrogen; ORA; —N(RA)2; —NHRA; substituted or unsubstituted acyl; —C(?O)ORA; —C(?O)N(RA)2; —CHO; or —NHC(?O)RA; and

RA is independently hydrogen or C1-C6 alkyl.

US Pat. No. 9,470,956

DIRECT ENTANGLED TRIPLET-PHOTON SOURCES AND METHODS FOR THEIR DESIGN AND FABRICATION

President And Fellows Of ...

1. A device for generating triplet photons, comprising:
a substrate exhibiting a linear refractive index equal to or less than about 1.6 for at least one radiation wavelength,
a waveguide disposed on said substrate and extending from a proximal end adapted to receive laser radiation from a pump source
at said wavelength, said waveguide comprising a radiation-propagating material exhibiting a linear refractive index equal
to or greater than about 1.8 and a third order non-linear refractive index equal to or greater than about 1×10?19 m2/W for said at least one radiation wavelength, said waveguide being configured to provide phase matching between at least
one propagating mode of said pump radiation and at least one propagating mode suitable for direct triplet entangled photons
generated via nonlinear interaction of the pump radiation with the waveguide, wherein said waveguide has a maximum cross-sectional
dimension in a range of about 100 nm to about 2000 nm and a maximum length (Lmax) defined by the following relation:


wherein ?p and ?s represent respectively coefficient of absorption plus scattering loss of said waveguide at the pump radiation wavelength and
at a wavelength of said at least one propagating mode for the direct triplet entangled photons.

US Pat. No. 9,363,991

SYSTEMS, METHODS, AND DEVICES FOR FROZEN SAMPLE DISTRIBUTION

President and Fellows of ...

1. A frozen tissue micro-arrayer comprising:
a coring bit;
a robotic positioning system configured to move the coring bit into a frozen tissue specimen while the tissue specimen remains
frozen to cut a frozen sample core from the frozen tissue specimen, withdraw the coring bit from the frozen tissue specimen
while the frozen sample core is retained in the coring bit, and move the coring bit and the frozen sample core to a destination
location for receiving the frozen sample core, wherein the robotic positioning comprises a motor configured to drive a rotary
motion of the coring bit as it moves the coring bit into the frozen tissue specimen to generate a rotary cutting action; and

an ejection system configured to eject the frozen sample core from the coring bit to deposit the frozen sample core at the
destination location,

wherein the robotic positioning system is adapted to control forces associated with the rotary cutting action to substantially
maintain an initial tissue morphology of the frozen tissue specimen during the cutting process.

US Pat. No. 9,353,646

SLIPPERY SURFACES WITH HIGH PRESSURE STABILITY, OPTICAL TRANSPARENCY, AND SELF-HEALING CHARACTERISTICS

President and Fellows of ...

1. An article having a repellant surface, the article comprising:
a substrate comprising a roughened surface having one or more functional groups chemically attached thereto; and
a lubricating liquid having an affinity for the substrate, the lubricating liquid wetting spontaneously and adhering to the
functionalized roughened surface to form a stabilized liquid overlayer, wherein the lubricating liquid covers the roughened
surface at a thickness sufficient to form a liquid upper surface above the roughened surface,

wherein the functionalized roughened surface and the lubricating liquid have a chemical affinity for each other such that,
at atmospheric pressure, the lubricating liquid is substantially stably immobilized in, on and over the functionalized roughened
surface, without dewetting from the substrate, to form a repellant surface.

US Pat. No. 9,317,743

SYSTEM AND METHOD FOR AUTOMATICALLY DISCOVERING, CHARACTERIZING, CLASSIFYING AND SEMI-AUTOMATICALLY LABELING ANIMAL BEHAVIOR AND QUANTITATIVE PHENOTYPING OF BEHAVIORS IN ANIMALS

President and Fellows of ...

1. A method for automatically discovering, characterizing and classifying the behavior of an animal in an experimental area,
comprising:
(a) using a 3D depth camera to obtain a video stream having a plurality of images of the experimental area with the animal
in the experimental area, the images having both area and depth information;

(b) removing background noise from each of the plurality of images to generate processed images having light and dark areas;
(c) determining contours of the light areas in the plurality of processed images;
(d) extracting parameters from both area and depth image information within the contours to form a plurality of multi-dimensional
data points, each data point representing the posture of the animal at a specific time and identifying the animal's head and
tail based on a derivative of the contour curvature;

(e) clustering the data points at each specific time to output a set of clusters that are segmented form each other so that
each cluster represents an animal behavior;

(f) assigning each cluster a label that represents an animal behavior; and
(g) outputting a visual representation of the set of clusters and corresponding labels.
US Pat. No. 9,066,905

SYNTHETIC PEPTIDES AND METHODS OF USE FOR AUTOIMMUNE DISEASE THERAPIES

President and Fellows of ...

1. A synthetic peptide capable of binding to an HLA-molecule associated with an autoimmune disease as represented in Table
2, said peptide having the amino acid sequence comprising at least three residues selected from the group of amino acids consisting
of aromatic amino acids, positively charged amino acids, and aliphatic amino acids, wherein one amino acid of the peptide
is tyrosine (Y), the positively charged amino acid is lysine (K) and the sequence comprises Lysine-tyrosine (KY), and
i. the peptide further comprises two alanine residues, and the sequence comprises alanine-lysine-tyrosine-alanine-glutamic
acid (AKYAE; SEQ ID NO: 54), and

ii. the aliphatic amino acid is alanine, andthe said synthetic peptide is nine to fifteen amino acid residues in length and presents a KY binding motif capable of competitive
binding to a cleft of an MHC class II protein, the protein is an HLA-DR molecule associated with an autoimmune disease as
represented in Table 2, and the Y amino acid residue of the KY binding motif is at an anchor position within the cleft of
said HLA-DR molecule.

US Pat. No. 9,140,606

HETERODYNE OFF-AXIS INTEGRATED CAVITY OUTPUT SPECTROSCOPY

President and Fellows of ...

1. An absorption spectroscopy instrument comprising:
a light source for providing a beam of light;
a means for modulating said beam of light by one tone where a modulation frequency is larger than an absorption bandwidth
of a target chemical;

a optical cavity comprising a pair of mirrors defining an axial light path in said optical cavity;
means for injecting said modulated beam of light off-axis into said optical cavity;
a detector positioned to detect light exiting through said optical cavity; and
means for demodulating light detected by said detector and extracting a component that is modulated at one of an applied modulation
frequency or a harmonic of an applied modulation frequency.

US Pat. No. 9,074,199

MUTANT CAS9 PROTEINS

President and Fellows of ...

1. A method of making a mutant Cas9 protein having DNA binding activity comprising
aligning full length amino acid sequences of a family of Cas9 proteins,
identifying one or more diverging amino acid sequence portions among the full length amino acid sequences of the family of
Cas9 proteins,

identifying a nucleic acid sequence for the one or more diverging amino acid sequences portions,
generating a nucleic acid sequence for a target Cas9 protein which lacks the nucleic acid sequence for the one or more diverging
amino acid sequences portions, and

generating a mutant Cas9 protein from the generated nucleic acid sequence.

US Pat. No. 9,463,431

SCREENING ASSAYS AND METHODS

President and Fellows of ...

1. An apparatus comprising a moldable slab reversibly sealed to a substrate surface, said moldable slab comprising an array
of microwells, wherein each microwell has a side or diameter of less than 100 microns and contains not more than a single
or a few cell(s), wherein at least one of said microwells contains the single or few cell(s), wherein the single or few cell(s)
produce a cell-derived product in a volume of 10 nanoliters or less of fluid in each said microwell containing the single
or few cell(s); wherein the surface of the substrate facing each said microwell containing said single or few cell(s) is bound
to the cell-derived product from said single or few cell(s) in their respective microwell.
US Pat. No. 9,572,854

TREATMENT OF PROTEIN DEGRADATION DISORDERS

President and Fellows of ...

1. A method of treating a subject suffering from a solid tumor comprising administering to the subject a therapeutically effective
amount of a proteasome inhibitor and an aggresome inhibitor, wherein the aggresome inhibitor selectively inhibits HDAC6.

US Pat. No. 9,415,550

SYSTEM, METHOD, AND COMPUTER-ACCESSIBLE MEDIUM FOR FABRICATION MINIATURE ENDOSCOPE USING SOFT LITHOGRAPHY

The General Hospital Corp...

1. A method for providing a diffractive configuration in an optical arrangement, comprising:
providing an elastomeric material with at least one patterned surface;
connecting the elastomeric material with at least one portion of a waveguide arrangement using a pre-polymer adhesive composition;
and

causing the pre-polymer adhesive composition to polymerize so as to form the diffractive configuration which at least approximately
replicates a structure or at least one feature of the elastomeric material.

US Pat. No. 9,410,946

QUALITY CONTROL BIOASSAYS FOR NUTRICEUTICAL AND MEDICINAL PRODUCTS

President and Fellows of ...

1. An in vitro method for identifying whether a sample contains n-3 polyunsaturated fatty acid (PUFA) activity comprising
the steps of:
providing a first test system including a first mRNA sequence encoded by a first biomarker gene having a coding region for
a first reporter protein operably linked to a first biomarker promoter;

providing a second test system including a second mRNA sequence encoded by a second biomarker gene having a coding region
for a second reporter protein operably linked to a second biomarker promoter;

contacting said second test system with the sample; and detecting transcription levels of said first and said second mRNA
sequences, and

identifying the sample as containing PUFA activity if the sample mediates transcriptional upregulation of the second biomarker
gene or (b) wherein the transcription level of said second mRNA sequence is greater than the transcription level of said first
mRNA sequence, and wherein said first and said second biomarker genes are members selected from the group consisting of nucleic
acid sequences that encode pro-apoptotic C/EBP homologous protein (CHOP), ER chaperone binding protein (BiP), Activating Transcription
Factor 4 (ATF-4), and X-box binding protein 1 (Xbp-1).

US Pat. No. 9,384,320

METHODS OF STORING INFORMATION USING NUCLEIC ACIDS

President and Fellows of ...

1. A method of storing information using nucleotides comprising
converting a format of information into a plurality of bit sequences of a bit stream with each having a corresponding bit
barcode,

converting the plurality of bit sequences to a plurality of corresponding oligonucleotide sequences using one bit per base
encoding,

synthesizing the plurality of corresponding oligonucleotide sequences, and
storing the synthesized plurality of corresponding oligonucleotide sequences.
US Pat. No. 9,260,519

FRIZZLED 2 AS A TARGET FOR THERAPEUTIC ANTIBODIES IN THE TREATMENT OF CANCER

PRESIDENT AND FELLOWS OF ...

1. A method of treating cancer in a subject that exhibits overexpression of Fzd2 or overexpression of Wnt5a comprising administering
to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds
Fzd2 within a region corresponding to amino acids 125-163 and downmodulates Fzd2, such that the antibody or antigen binding
fragment thereof is delivered to cancer cells of the subject, to thereby treat the cancer.
US Pat. No. 9,150,631

ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT

President and Fellows of ...

1. A recombinant opsonin comprising: a carbohydrate recognition domain of mannose binding lectin (MBL) consisting of (i) SEQ
ID NO: 2 or (ii) amino acid residues 31 (glycine) to 148 (isoleucine) of SEQ ID NO:2; and a peptide comprising a portion of
an immunoglobulin Fc that links to the carbohydrate recognition domain.

US Pat. No. 9,410,267

METHODS AND DEVICES FOR THE FABRICATION OF 3D POLYMERIC FIBERS

President and Fellows of ...

1. A device for the fabrication of a submicron or nanometer dimension polymeric fiber, comprising
a rotary spinning system, said system comprising
a rotating reservoir suitable for accepting a polymer and comprising an orifice having a diameter of about 1 micrometer to
about 400 micrometers, the orifice configured to form a submicron or nanometer dimension polymeric fiber by ejecting a jet
of said polymer radially outward from the orifice during rotation of said reservoir at a rotational speed of about 24,000
rpm to about 50,000 rpm;

a motor for imparting rotational motion to the reservoir, the motor being configured to impart a rotational speed of about
24,000 rpm to about 50,000 rpm to the reservoir;

a collector for accepting said formed submicron or nanometer dimension polymeric fiber, at least a portion of the collector
disposed directly radially outward from the rotating reservoir; and

a flexible air foil for facilitating collection of said radially ejected submicron or nanometer dimension polymeric fiber
on the portion of the collector disposed directly radially outward from the rotating reservoir, the flexible air foil being
attached to a shaft of the motor above the reservoir;

wherein the device is free of an electrical field.

US Pat. No. 9,351,900

SOFT EXOSUIT FOR ASSISTANCE WITH HUMAN MOTION

President and Fellows of ...

1. A wearable soft exosuit comprising:
a first anchor element configured for positioning at or near a first body part of a person wearing the wearable soft exosuit;
a second anchor element configured for positioning at or near a second body part of the person wearing the wearable soft exosuit;
an actuation member coupled to the second anchor element configured to be behind an ankle joint of the person;
a plurality of connection elements extending between and connected directly or indirectly to the first anchor element and
the actuation member, and at least one of the plurality of connection elements spanning at least one joint disposed between
the first anchor element and the second anchor element;

at least one actuator; and
at least one controller configured to actuate the at least one actuator at a predetermined time during movement of the at
least one joint to generate a beneficial moment about the at least one joint,

wherein each of the plurality of connection elements comprise webbing, a strap, a cord, a functional textile, fabric, a wire,
a cable, or a composite material,

wherein the at least one actuator comprises at least one motor driven actuator, at least one pneumatic actuator, or at least
one hydraulic actuator,

wherein the second anchor element comprises a footwear anchor element,
wherein the first anchor element comprises a waist belt anchor element,
wherein the at least one actuator is configured to apply a tensile force to the second anchor element via the actuation member,
wherein the plurality of connection elements comprise a first connection element on a first side of the waist belt anchor
element configured to extend from the waist belt to a position adjacent a center of the wearer's first thigh, a second connection
element on the first side of the waist belt anchor element configured to extend from the waist belt to a position adjacent
a center of the wearer's second thigh, a third connection element on a second side of the waist belt anchor element configured
to extend from the waist belt to a position adjacent a center of the wearer's second thigh, and a fourth connection element
on the second side of the waist belt anchor element configured to extend from the waist belt to a position adjacent a center
of the wearer's first thigh,

wherein the first connection element and the fourth connection element are connected to form a first node at the position
adjacent the center of the wearer's first thigh, and

wherein the second connection element and the third connection element are connected to form a second node at the position
adjacent the center of the wearer's second thigh.

US Pat. No. 9,200,045

SMALL MOLECULE-DEPENDENT INTEINS AND USES THEREOF

President and Fellows of ...

1. A ligand-dependent intein comprising an amino acid as provided in SEQ ID NO: 2 wherein the intein comprises at least one
mutation selected from the group consisting of V34A, I66T, E375G, L124P, D129N, C178R, and T328K, and wherein the ligand-dependent
intein does not comprise the amino acid sequence provided in SEQ ID NO: 1.
US Pat. No. 9,157,062

COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF PDX1+ PANCREATIC CELLS

President and Fellows of ...

1. A method of producing pancreatic Pdx1-expressing cells comprising:
a) exposing a population of human embryonic stem (hES) cells to an effective amount of at least one compound listed in Table
1 and a compound selected from the group consisting of FGF10, Wnt3?, Activin A, Activin B and KAAD-cyclopamine to differentiate
the hES cells into definitive endoderm cells, and

b) obtaining a population of definitive endoderm cells which has increased expression of Pdx1 compared to a population of
hES cells which were not exposed to a compound listed in Table 1.

US Pat. No. 9,137,516

SUB-DIFFRACTION LIMIT IMAGE RESOLUTION IN THREE DIMENSIONS

President and Fellows of ...

1. A microscope apparatus comprising:
an illumination system that irradiates light to activate and excite a fraction of a plurality of entities in a sample;
an imaging system comprising an objective lens, wherein the imaging system forms a plurality of astigmatism images of the
fraction of the plurality of entities by fluorescence light emitted from the fraction of the plurality of entities on a detector;

a controller for repeatedly irradiating the light to the sample through the illumination system; and
a processer that determines x, y, and z positions of at least some of the plurality of entities in the sample based on the
plurality of astigmatism images, wherein the x, y, and z positions of the plurality of entities are 3-D spatial coordinates
and are each determined to a precision better than the wavelength of the light emitted by at least some of the plurality of
entities.

US Pat. No. 9,285,575

SYSTEMS AND METHODS FOR SELECTIVE DETECTION AND IMAGING IN COHERENT RAMAN MICROSCOPY BY SPECTRAL EXCITATION SHAPING

PRESIDENT AND FELLOWS OF ...

1. A microscopy imaging system comprising:
a light source system for providing a first train of pulses including a first broadband range of frequency components, and
a second train of pulses including a second optical frequency such that a set of differences between the first broadband range
of frequency components and the second optical frequency is resonant with a set of vibrational frequencies of a sample in
the focal volume, wherein the second train of pulses is synchronized with the first train of pulses;

a spectral shaper including a dispersing element for spectrally dispersing frequency components of the broadband range of
frequency components, spectrally modifying an optical property of at least some frequency components of the broadband range
of frequency components, and spectrally combining using the dispersing element, the modified frequency components such that
the broadband range of frequency components is shaped producing a shaped first train of pulses to specifically probe a spectral
feature of interest from a sample, and to reduce information from features that are not of interest from the sample;

a modulator system for modulating a property of at least one of the shaped first train of pulses and the second train of pulses
at a modulation frequency to provide a modulated train of pulses;

an optics system for directing and focusing the shaped first train of pulses and the second train of pulses as modulated toward
a common focal volume;

an optical detector for detecting an integrated intensity of substantially all optical frequency components of a train of
pulses of interest transmitted or reflected through the common focal volume; and

a processor for detecting a modulation at the modulation frequency of the integrated intensity of substantially all of the
optical frequency components of the train of pulses of interest due to the non-linear interaction of the shaped first train
of pulses with the second train of pulses as modulated in the common focal volume, and for providing an output signal for
a pixel of an image for the microscopy imaging system;

wherein only one of the shaped train of laser pulses or the second train of pulses is modulated at the modulation frequency
to provide the modulated train of pulses such that the other of the shaped train of laser pulses and the second train of pulses
remains a non-modulated train of pulses;

wherein the optical detector detects the integrated intensity of substantially all optical frequency components of the non-modulated
train of pulses transmitted or reflected through the common focal volume by blocking the modulated train of pulses; and

wherein the processor detects a modulation at the modulation frequency of the integrated intensity of substantially all of
the optical frequency components of the non-modulated train of pulses due to the non-linear interaction of the modulated train
of pulses with the non-modulated train of pulses in the common focal volume.

US Pat. No. 9,193,705

SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES AND METHODS OF USE

President and Fellows of ...

1. A compound represented by formula II:
or a pharmaceutically acceptable salt, solvate, hydrate, chemically-protected form, enantiomer or stereoisomer thereof; wherein,
independently for each occurrence,

L1 is


L2 is


l1 is a bond to L1;

l2 is a bond to L2;

a1 is a bond to


a2 is a bond to


a3 is a bond to


X is a bond,

R3 is hydrogen or alkyl;

R4 is hydrogen, alkyl, aralkyl, or alkylcarbonyl; and

R5 is hydrogen, or alkyl, haloalkyl, or alkyl substituted with hydroxy, cyano, carboxy, aralkyloxy, alkyloxycarbonyl or aralkyloxycarbonyl;

provided that the compound is not

US Pat. No. 9,228,207

SWITCHABLE GRNAS COMPRISING APTAMERS

President and Fellows of ...

1. A switchable single-guide RNA (sgRNA), comprising
(1) an sgRNA backbone sequence, wherein the sgRNA backbone sequence comprises a nucleotide sequence that is at least 90% identical
to the nucleotide sequence 5?- GUUUUAGAGC UAUGCUGAAA AGCAUAGCAA GUUAAAAUAA GGCUAGUCCG UUAUC -3?(nucleotides 79-133 of SEQ
ID NO: 6) and/or at least 90% identical to the nucleotide sequence 5?- GUUUUAGAGC UAUGCUGAAA AGCAUAGCAA GUUAAAAU -3?(nucleotides
22-59 of SEQ ID NO: 9);

(2) an RNA aptamer comprising a riboswitch, wherein the aptamer comprises 20-100 nucleotides, and wherein the riboswitch is
selected from a theophylline riboswitch, a thiamine pyrophosphate (TPP) riboswitch, an adenosine cobalamin (AdoCbl) riboswitch,
an S-adenosyl methionine (SAM) riboswitch, an SAH riboswitch, a flavin mononucleotide (FMN) riboswitch, a tetrahydrofolate
riboswitch, a lysine riboswitch, a glycine riboswitch, a purine riboswitch, a GlmS riboswitch, or a pre-queosinel (PreQ1)
riboswitch; and

(3) a guide sequence that is complementary to a DNA target site,
wherein the DNA target site comprises the structure 5?-[Nz]-[protospacer adjacent motif (PAM)]-3?, wherein

each N is, independently, any nucleotide, and
Z is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35,
36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50;

wherein the guide sequence of (3) is flanked by the riboswitch of (2) on one side and by the sgRNA backbone sequence of (1)
on the other side; and

wherein the riboswitch of (2) comprises a sequence of at least 4 contiguous nucleotides that is complementary to the guide
sequence.

US Pat. No. 9,446,107

SCAFFOLDS FOR CELL TRANSPLANTATION

President and Fellows of ...

1. A cancer vaccine device comprising a scaffold composition comprising a polymer matrix and having open, interconnected macropores;
a granulocyte-macrophage colony stimulating factor (GM-CSF) that recruits immune cells selected from macrophages, T-cells,
B-cells, NK cells, and dendritic cells;

a tumor antigen; and
an immune response-promoting bioactive factor comprising an oligonucleotide, wherein the GM-CSF, the tumor antigen, or the
immune response-promoting bioactive factor is incorporated into or coated onto said scaffold composition.

US Pat. No. 9,284,297

HALOFUGINONE ANALOGS FOR INHIBITION OF TRNA SYNTHETASES AND USES THEREOF

President and Fellows of ...

1. A compound of formula (I):
wherein
j is an integer between 0 and 10, inclusive;
p is an integer between 0 and 6, inclusive;
q is an integer between 0 and 6, inclusive;
m is 1 or 2;
v is an integer between 1 and 3, inclusive;
X is N or CRX, wherein RX is hydrogen; halogen; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or
unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORF; —SRF; —N(RF)2; and —C(RF)3; wherein each occurrence of RF is independently a hydrogen; a halogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety;
an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy;
or heteroarylthioxy moiety;

each occurrence of Y is independently S, O, N, NRY, C or CRY, wherein each occurrence of RY is independently hydrogen; halogen; substituted or unsubstituted heteroaryl; —ORG; —C(?O)RG; —CO2RG; —C(?O)N(RG)2; —CN; —SCN; —SRG; —SORG; —SO2RG; —NO2; —N(RG)2; or —NHC(O)RG; wherein each occurrence of RG is independently a hydrogen; a halogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety;
an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy;
or heteroarylthioxy moiety, wherein one, two, or three occurrences of Y are CH;

each occurrence of T and G is independently —S—, —O—, —NRE—, or —C(RE)2—, wherein each occurrence of RE is independently hydrogen; halogen; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic;
substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORG; —SRG; —N(RG)2; and —C(RG)3; wherein each occurrence of RG is independently a hydrogen; a halogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety;
an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy;
or heteroarylthioxy moiety;

R1 is hydrogen; a protecting group; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic
or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or
unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —C(?O)RA; —C(?O)ORA; —C(?O)N(RA)2; or —C(RA)3; wherein each occurrence of RA is independently a hydrogen; a halogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety;
an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy;
or heteroarylthioxy moiety;

each occurrence of R2 is independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic
or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or
unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORB; —C(?O)RB; —CO2RB; —C(?O)N(RB)2; —CN; —SCN; —SRB; —SORB; —SO2RB; —NO2; —N(RB)2; —NHC(O)RB; or —C(RB)3; wherein each occurrence of RB is independently a hydrogen; a halogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety;
an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy;
or heteroarylthioxy moiety;

R3 is halogen; —OH; or —CO2RC; wherein each occurrence of RC is independently a hydrogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety; an aryl moiety;
or a heteroaryl moiety;

R4 and R5 are independently hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic
or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or
unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl; —ORD; —C(?O)RD; —CO2RD; —C(?O)N(RD)2; —CN; —SCN; —SRD; —SORD; —SO2RD; —NO2; —N(RD)2; —NHC(O)RD; or —C(RD)3; wherein each occurrence of RD is independently a hydrogen; a halogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety;
an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy;
or heteroarylthioxy moiety; and

R6 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted
or unsubstituted, branched or unbranched acyl; substituted or unsubstituted aryl; substituted or unsubstituted heteroaryl;
—ORK; —C(?O)RK; —CO2RK; —C(?O)N(RK)2; —CN; —SCN; —SRK; —SORK; —SO2RK; —NO2; —N(RK)2; —NHC(O)RK; or —C(RK)3; wherein each occurrence of RK is independently a hydrogen; a halogen; a protecting group; an aliphatic moiety; a heteroaliphatic moiety; an acyl moiety;
an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthioxy; arylthioxy; amino; alkylamino; dialkylamino; heteroaryloxy;
or heteroarylthioxy moiety;

and pharmaceutically acceptable salts thereof.
US Pat. No. 9,284,602

COMPOSITIONS OF TOEHOLD PRIMER DUPLEXES AND METHODS OF USE

President and Fellows of ...

1. A partially double-stranded primer comprised of first and second nucleic acid strands arranged into
(1) one double-stranded target-non-specific region,
(2) one double-stranded target-specific region, and
(3) one single-stranded target-specific region contributed to by the first nucleic acid strand,
wherein the double-stranded target-non-specific region has a standard free energy that is within 10% of the standard free
energy for the single-stranded target-specific region bound to a perfectly complementary region of a target nucleic acid,
wherein the sequence of the first nucleic acid strand that contributes to region (1) is not perfectly complementary to and
does not bind to the target nucleic acid, and wherein the sequences of regions (2) and (3) are complementary to and bind to
the target nucleic acid.

US Pat. No. 9,186,425

METHODS FOR TUMOR DIAGNOSIS AND THERAPY

President and Fellows of ...

1. A method for delivering a radiation dose to a tissue in a subject, the method comprising:
(i) administering to a subject in need thereof an effective amount of a water-soluble prodrug molecule, wherein said prodrug
is represented by the formula:

wherein
R1 is selected from the group consisting of a hydrogen radical, a radionuclide, a molecule labeled with one or more radionuclides,
a boron atom, a moiety labeled with one or more boron atoms, and a boron cage;

R2 is selected from the group consisting of a hydrogen radical, a radionuclide, and a boron cage;

at least one of R1 and R2 is not a hydrogen radical; and

R3 is a prosthetic group that can be cleaved by an enzyme;

said prodrug being a substrate for the enzyme and hydrolyzed by said enzyme molecules present within the tissue, said hydrolysis
forming a water-insoluble drug precipitate, and

(ii) if R1 or R2 comprises at least one boron atom, activating the boron atom with epithermal neutrons;

such that a radiation dose is delivered to the tumor.

US Pat. No. 9,150,516

FLUORINATION OF ORGANIC COMPOUNDS

President and Fellows of ...

1. A compound of formula (I):

wherein
R1 and R2 are each independently selected from C6-12 aryl, C6-12 aralkyl, 6-12 membered heteroaryl, 6-12 membered heteroaralkyl, 6-12 membered heterocyclyl and 6-12 membered heterocyclylalkyl,
each of which is substituted with 0-3 occurrences of R5;

X is an optionally substituted C2-C5 alkenylene moiety

each R5 is independently selected from halo, C1-8 alkyl, C1-8 haloalkyl, C1-8 alkoxy, C6-12 aryl and 6-12 membered heteroaryl.

US Pat. No. 9,221,886

SUPERCHARGED PROTEINS FOR CELL PENETRATION

President and Fellows of ...

1. A supercharged protein associated with a functional peptide or protein, comprising
a supercharged protein having
a molecular weight of 4-100 kDa, a theoretical net charge of at least +10 at physiological pH, and a charge to molecular weight
ratio of at least 0.8, wherein the supercharged protein is a supercharged protein variant of a wild-type protein and comprises
a modified primary amino acid sequence as compared to the wild-type sequence,

wherein the modified primary amino acid sequence comprises replacement of a plurality of charged or polar, solvent-exposed
residues with a natural amino acid residue that is positively charged at physiological pH; and

a functional peptide or protein selected from the group consisting of enzymes, DNA-binding proteins, histones, cytoskeletal
proteins, receptor proteins, chaperone proteins, transcription factors, tumor suppressors, developmental regulators, growth
factors, metastasis suppressors, pro-apoptotic proteins, and reprogramming factors,

wherein the supercharged protein is covalently bound to the functional peptide or protein, and wherein the supercharged protein
associated with the functional peptide or protein is able to penetrate a cell and deliver the functional peptide or protein
to the cell.

US Pat. No. 9,508,266

CROSS-CLASSROOM AND CROSS-INSTITUTION ITEM VALIDATION

PRESIDENT AND FELLOWS OF ...

1. A server for pretesting items for subsequent presentation to participants in a target class, the system comprising:
a processor; and
a computer readable medium comprising instructions to perform the operations comprising:
transmitting, by the server, an item to devices associated with a potential set of students, wherein the item is presented
by the devices associated with the potential set of students;

receiving first student input data from at least some of the devices associated with the potential set of students, wherein
the first student input data is received in response to presenting the item to the potential set of students;

receiving at least one value of a characteristic associated with students in the potential set of students, wherein the characteristics
corresponds with a demographic characteristic, a behavioral characteristic, or a performance characteristic of the students;

pruning, by the server, at least one of the first student input data received in response to presenting the item from the
potential set of students to form a composite class of remaining students, wherein the composite class of remaining students
comprises the first student input data and the composite class of remaining students is associated with a value matching the
at least one value of the characteristic;

transmitting a post task question to at least some of the devices associated with the composite class of remaining students;
receiving second student input data in response to the post task question;
creating guidance on revising the item based at least in part on the first student input data or second student input data
received from the devices associated with the composite class of remaining students; and

transmitting, by the server, the guidance for revising the item to an instructor device associated with the target class.

US Pat. No. 9,358,539

VALVES AND OTHER FLOW CONTROL IN FLUIDIC SYSTEMS INCLUDING MICROFLUIDIC SYSTEMS

President and Fellows of ...

1. A microfluidic system, comprising:
a delivery channel;
a first channel section and a second channel section, wherein the first channel section and the second channel section are
each downstream of and fluidly connected to the delivery channel at a junction, the second channel section having a higher
hydrodynamic resistance than the first channel section;

a valve comprising a control channel adjacent the first channel section and not fluidly connected to the first channel section,
wherein actuation of the valve adjusts hydrodynamic resistance of the first channel section, but does not result in variation
in the amount of fluid flow through the second channel section; and

a membrane positioned between the first channel section and the control channel,
wherein the control channel is constructed and arranged to cause deflection of the membrane, resulting in constriction of
at least a portion of the first channel section such that the first channel section has a higher hydrodynamic resistance than
the second channel section,

wherein at least a portion of the control channel is on the same horizontal plane as the first channel section, and
wherein the second channel section does not include a valve able to vary its hydrodynamic resistance;
the microfluidic system further comprising a fluid containing droplets, the fluid contained within the delivery channel and
flowing towards the junction into both the first channel section and the second channel section, wherein deflection of the
membrane via the control channel controls the flow of droplets into the first channel section or the second channel section
without preventing the flow of fluid into both the first channel section and the second channel section.

US Pat. No. 9,826,622

REDUCING NOISE AND TEMPERATURE DURING MEASUREMENTS IN CRYOSTATS

PRESIDENT AND FELLOWS OF ...

1. A device to reduce noise and temperature during measurements in a cryostat, said device comprising each of the following
PC boards, with each conditioning a different frequency range: a RC-PC board having a two-stage RC filter in series with a
surface-mounted pi-filter; a RF-PC board having a plurality of surface-mounted pi-filters in series, each configured with
different low-frequency cutoff frequencies; and a Sapphire-PC board having a sapphire substrate having high heat conductivity
at low temperature with thin film metal wires routed in a pre-defined fashion, the RC-PC serves as structural support for
a plurality of electrical connectors, the electrical connection between the electrical connectors and the thin film metal
wires is configured to provide cooling and noise reduction to multiple signal lines simultaneously.

US Pat. No. 9,409,265

THREE DIMENSIONAL ASSEMBLY OF DIAMAGNETIC MATERIALS USING MAGNETIC LEVITATION

President and Fellows of ...

1. A method of assembling two or more objects into a three-dimensional structure, comprising:
introducing two or more diamagnetic objects into a paramagnetic solution, the paramagnetic solution comprising a paramagnetic
material in a solvent; and

applying a magnetic field to the paramagnetic solution to assemble the two or more objects into a three-dimensional structure;
wherein

each of said two or more objects has an overall density that levitates the components in a particular height within said magnetic
field and at least one of the objects having a non-uniform density profile that orients the components in a particular orientation
within said magnetic field.

US Pat. No. 9,394,537

CONTINUOUS DIRECTED EVOLUTION

President and Fellows of ...

1. A method of phage-assisted continuous evolution, comprising
(a) contacting a population of bacterial host cells in a culture medium with a population of M13 phages comprising a gene
of interest to be evolved and lacking a functional pIII gene required for the generation of infectious phage particles, wherein

(1) the M13 phages allow for expression of the gene of interest in the host cells,
(2) the host cells are suitable host cells for M13 phage infection, replication, and packaging, wherein the M13 phage comprises
all phage genes required for the generation of phage particles, except a full length pIII gene; and

(3) the host cells comprise an expression construct encoding the pIII protein, wherein expression of the pIII gene is dependent
on a function of a gene product of the gene of interest;

(b) incubating the population of host cells under conditions allowing for the mutation of the gene of interest, the production
of infectious M13 phage, and the infection of host cells with M13 phage, wherein infected cells are removed from the population
of host cells, and wherein the population of host cells is replenished with fresh host cells that are not infected by M13
phage, wherein the function of the gene of interest is a desired function, wherein desired functional library members induce
production of pIII and release M13 progeny into the culture medium capable of infecting new host cells, wherein undesired
non-functional library members do not produce pIII and release only non-infectious M13 progeny into the culture medium;

(c) isolating a mutated M13 phage replication product encoding an evolved protein from the population of host cells, wherein
the host cells comprise an expression construct encoding a dominant-negative pIII protein (pIII-neg), wherein the pIII-neg
protein is driven by a promoter the activity of which depends on an undesired function of a gene product encoded by the gene
of interest.

US Pat. No. 9,276,143

SILICON-BASED VISIBLE AND NEAR-INFRARED OPTOELECTRIC DEVICES

President And Fellows Of ...

1. A method of processing a semiconductor substrate, comprising
depositing a solid charge-donating substance on a surface of a semiconductor substrate,
subsequently, irradiating said surface with a plurality of laser pulses having a pulse width in a range of about 50 femtoseconds
to about 50 picoseconds incorporating at least a portion of said solid charge-donating substance into a surface layer of said
semiconductor substrate at a concentration in a range of about 0.5 to about 5 atom percent,

wherein a diode junction is formed with an underlying portion of the substrate.

US Pat. No. 9,527,896

STABILIZED P53 PEPTIDES AND USES THEREOF

DANA-FARBER CANCER INSTIT...

1. A peptide of Formula (I),
or a pharmaceutically acceptable salt thereof,wherein:
each R1 and R2 is independently H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclylalkyl;

each R3 is independently alkyl, alkenyl, alkynyl, or [R4—K—R4?]n, each of which is independently substituted with 0-6 R5;

each R4 and R4? is independently alkylene, alkenylene or alkynylene;

each R5 is independently halo, alkyl, OR6, N(R6)2, SR6, SOR6, SO2R6, CO2R6, R6, a fluorescent moiety, or a radioisotope;

each K is independently O, S, SO, SO2, CO, CO2, CONR6, or


each R6 is independently H, alkyl, or a therapeutic agent;

each n is independently an integer from 1-4;
each x is 6;
each y is independently an integer from 0-100;
each w is independently an integer from 0-100;
z is an integer from 1-10; and
each Xaa is independently an amino acid;
wherein the peptide comprises 8 contiguous amino acid residues, wherein the 8 contiguous amino acid residues comprise Phe,
Leu, and Trp, wherein the peptide exhibits a binding affinity for HDM2 that is from about 0.75 nM to about 110 nM, wherein [Xaa]x prises the Leu and the Trp.

US Pat. No. 9,425,406

GAS-PHASE FUNCTIONALIZATION OF SURFACES OF MICROELECTRONIC STRUCTURES

President and Fellows of ...

1. A method for functionalizing an inert planar surface of a microelectronic structure comprising:
providing a planar microelectronic structure surface that is chemically inert to material layer deposition precursors;
exposing the inert planar microelectronic structure surface to at least one vapor including at least one functionalization
specie that is physisorbed but not chemisorbed on the inert microelectronic structure surface and that is not a metal that
changes electrical state of the microelectronic structure, to non-covalently bond to the inert planar microelectronic structure
surface while providing a functionalization layer of chemically-active functional groups, to produce a functionalized planar
microelectronic structure surface that is reactive to material layer deposition precursors;

exposing the functionalized planar microelectronic structure surface to at least one vapor stabilization species that reacts
with the functionalization layer to form a stabilization layer that stabilizes the functionalization layer against desorption
from the planar microelectronic structure surface while providing chemically-active functional groups at the planar microelectronic
structure surface, to produce a stabilized planar microelectronic structure surface; and

exposing the stabilized planar microelectronic structure surface to at least one material layer precursor species that deposits
a material layer on the stabilized planar microelectronic structure surface.

US Pat. No. 9,290,591

IRON COMPLEXES AND METHODS FOR POLYMERIZATION

President and Fellows of ...

1. A method of preparing a polymer, the method comprising polymerizing one or more alkenes in the presence of an iron complex,
wherein the iron complex comprises a ligand of the Formula (BI-a):
wherein:
m is 0 or 1, provided that when m is 0, X is selected from N—R4; and when m is 1, X is selected from N or C—R4;

each instance of R1, R2, R3, R4, and R5 is independently selected from the group consisting of hydrogen, halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —SH, —NH2, substituted hydroxyl, substituted thiol, monosubstituted amino, disubstituted amino, trisubstituted amino, sulfonyl, sulfinyl,
carbonyl, silyl, phosphino, boronyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted
alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally
substituted heteroaryl; or R1 and R2, or R2 and R3, or R2 and R4, or R3 and R4, are optionally joined to form a ring selected from the group consisting of optionally substituted carbocyclyl, optionally
substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl ring;

R7 is optionally substituted aryl or optionally substituted —CH2aryl;

R8 and R9 are each independently selected from the group consisting of hydrogen, halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —SH, —NH2, substituted hydroxyl, substituted thiol, monosubstituted amino, disubstituted amino, trisubstituted amino, sulfonyl, sulfinyl,
carbonyl, silyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally
substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl,

and the one or more alkenes are independently an optionally substituted 1,3-diene of formula (i):
wherein:
each instance of Ra, Rb, Rc, Rd, Re, and Rf is independently selected from the group consisting of hydrogen, silyl, optionally substituted alkyl, optionally substituted
alkenyl, optionally substituted alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally
substituted aryl, and optionally substituted heteroaryl;

or Ra and Rf are joined to form an optionally substituted heterocyclyl or optionally substituted carbocyclyl ring.

US Pat. No. 9,279,771

MANIPULATION OF FLUIDS IN THREE-DIMENSIONAL POROUS PHOTONIC STRUCTURES WITH PATTERNED SURFACE PROPERTIES

President and Fellows of ...

1. A suspension comprising:
a plurality of non-spherical, microstructured photonic crystal particles suspended in a liquid medium, each particle comprising
a porous three-dimensional photonic crystal, said photonic crystal comprising a matrix material defining a plurality of pores
and a plurality of nanoparticles dispersed within the matrix material,

wherein said plurality of non-spherical, microstructured photonic crystal particle are obtained by templating against a microstructured
surface to form photonic crystal particles that have a non-spherical shape defined by the microstructured surface;

wherein the size of the particles, the size of the pores of the photonic crystal, and the size of the nanoparticles provide
a response in the visible wavelengths.

US Pat. No. 9,708,648

HIC: METHOD OF IDENTIFYING INTERACTIONS BETWEEN GENOMIC LOCI

University of Massachuset...

1. A method for identifying an interaction frequency, comprising;
a) providing;
i) a cell comprising at least one chromosome, wherein said at least one chromosome comprises a first region and a second region;
and

ii) a junction marker;
b) extracting said at least one chromosome from said cell;
c) incorporating said junction marker into said extracted chromosome; and
d) identifying an interaction frequency between said first region and said second region.

US Pat. No. 9,104,030

LASER ILLUMINATION SYSTEMS AND METHODS FOR DUAL-EXCITATION WAVELENGTH NON-LINEAR OPTICAL MICROSCOPY AND MICRO-SPECTROSCOPY SYSTEMS

PRESIDENT AND FELLOWS OF ...

1. An illumination system for providing dual-excitation wavelength illumination for non-linear optical microscopy and micro-spectroscopy,
said illumination system comprising:
a laser system including a laser for providing a first train of pulses at a center optical frequency ?1;

an optical splitting means for dividing the first train of pulses at the center optical frequency ?1 into a first split train of pulses and a second split train of pulses;

a frequency shifting system for shifting the optical frequency of the first split train of pulses to provide a frequency shifted
train of pulses;

an amplifier system for amplifying the frequency-shifted train of pulses to provide an amplified frequency-shifted train of
pulses;

combining means for combining the amplified frequency-shifted train of pulses with the second split trains of pulses to provide
the amplified frequency-shifted train of pulses and the second split trains of pulses as a collinear train of laser pulses
for the dual-excitation wavelength illumination; and

adjustment means for adjusting a time delay between the amplified frequency-shifted train of pulses and the second split train
of pulses.

US Pat. No. 9,068,699

MANIPULATION OF FLUIDS, FLUID COMPONENTS AND REACTIONS IN MICROFLUIDIC SYSTEMS

Brandeis University, Wal...

1. A method for partitioning a fluid, comprising the steps of:
(a) providing a microfluidic network comprising a first fluid channel and a second fluid channel, wherein hydrodynamic resistance
in the second fluid channel is lower than hydrodynamic resistance in the first fluid channel and wherein the first fluid channel
and the second fluid channel are in fluid communication with a first region;

(b) flowing a first fluid through the first fluid channel, the first region, and the second fluid channel, wherein the first
fluid causes hydrodynamic resistance in the second fluid channel to be higher than hydrodynamic resistance in the first fluid
channel; and

(c) flowing a second fluid in the first fluid channel, wherein the second fluid is immiscible with the first fluid, and wherein
the second fluid bypasses the first region, thereby partitioning a portion of the first fluid in the first region.

US Pat. No. 9,108,923

COMPOUNDS, COMPOSITIONS, AND METHODS FOR CANCER THERAPY

Howard Hughes Medical Ins...

1. A compound having the formula:

wherein A is C(O) or S(O)2;

wherein B is alkenyl or alkynyl;
wherein n=0, 1, 2, or 3;
wherein R1 is selected from the group consisting of a hydrogen, C?C-alkyl, C?C-cycloalkyl, C?C-cycloalkyl halide, C?C-phenyl, C?C-thienyl,
and a C?C-phenyl halide wherein the halide is substituted ortho to the phenyl ring carbon that is bound to the alkynyl carbon;

wherein R2 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group;

wherein R3 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group; and,

wherein R4 is selected from the group consisting of:

(i) substituted phenyl when B is alkynyl and R1 is hydrogen,

(ii) a moiety of the formula:

 wherein, R5 is selected from the group consisting of hydrogen, halogen, and methoxy, and wherein each of R6, R7, and R8 are independently selected from the group consisting of hydrogen, bromine, chlorine, fluorine, keto, hydroxyl, alkyl, alkenyl,
alkoxy, an aminoalkenyl, and an aminoalkoxy group with the proviso that R4 is (III) only when R1 is not hydrogen,

(iii) a moiety of the formula:

 and
(iv) a moiety of the formula (V):

 wherein A is C(O) or S(O)2, wherein X, when present in (V), is an alkenyl, aryl, or combination thereof;

wherein n=0, 1, 2, or 3;
wherein R9 is selected from the group consisting of a hydrogen, C?C-alkyl, C?C-cycloalkyl, C?C-cycloalkyl halide, C?C-phenyl, C?C-thienyl,
and a C?C-phenyl halide wherein the halide is substituted ortho to the phenyl ring carbon that is bound to the alkynyl carbon;

wherein R10 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group; and,

wherein R11 is selected from the group consisting of hydrogen, alkyl, alkenyl, and an aryl group.

US Pat. No. 9,588,025

MANIPULATION OF FLUIDS, FLUID COMPONENTS AND REACTIONS IN MICROFLUIDIC SYSTEMS

Brandeis University, Wal...

1. A method of positioning a plurality of cells, comprising
providing a microfluidic network comprising a microfluidic inlet, a first region, and a second region, wherein the first region
and the second region are in fluid communication;

flowing a first fluid through the microfluidic inlet, the first region, and the second region, wherein the first fluid comprises
a plurality of cells; and

positioning a first cell in the first region, wherein said positioning prevents entry of another cell into the first region,
wherein the first cell is encapsulated in a droplet or a gel.

US Pat. No. 9,597,347

COMPOSITIONS FOR TREATING OBESITY AND INSULIN RESISTANCE DISORDERS

President and Fellows of ...

1. A method for treating an insulin resistance disorder in a subject in need thereof, comprising administering to the subject
nicotinamide riboside or a nicotinamide riboside analog represented by formula A:

wherein R represents independently for each occurrence H, acetyl, benzoyl, acyl, phosphate, sulfate, (alkyoxy)methyl, triarylmethyl,
(trialkyl)silyl, (dialkyl)(aryl)silyl,

(alkyl)(diaryl)silyl, or (triaryl)silyl; and X represents 0 or S, at a concentration of 1 nM to 10 ?M,
wherein the subject is a human subject.
US Pat. No. 9,439,909

COMPOSITIONS AND METHODS FOR SENSITIZING A NEOPLASTIC CELL TO RADIATION

The Broad Institute, Inc....

1. A method of sensitizing a non small cell lung cancer cell to radiation, the method comprising contacting the cell with
a PI3 kinase inhibitor and exposing the cell to radiation, thereby sensitizing the cell to radiation, wherein the cell comprises
a NFE2L2 mutation.

US Pat. No. 9,229,218

ENVIRONMENTALLY RESPONSIVE OPTICAL MICROSTRUCTURED HYBRID ACTUATOR ASSEMBLIES AND APPLICATIONS THEREOF

President and Fellows of ...

1. An apparatus comprising:
a substrate with a surface;
an environmentally responsive hydrogel polymer layer disposed on a region of the surface; and
a plurality of microactuators embedded in the environmentally responsive hydrogel polymer layer, wherein the plurality of
microactuators are a plurality of plates;
wherein the microactuators are configured to move from a first position to a second position in response to a volume change
of the environmentally responsive hydrogel polymer layer from a first volume to a second volume and wherein the movement of
microactuators alters optical properties of the apparatus.
US Pat. No. 9,737,480

ARRDC1-MEDIATED MICROVESICLES (ARMMS) AND USES THEREOF

President and Fellows of ...

1. An arrestin domain-containing protein 1 (ARRDC1)-mediated microvesicle (ARMM), comprising
(a) a lipid bilayer,
(b) an ARRDC1 protein or fragment thereof, and
(c) an agent selected from the group consisting of recombinant nucleic acids, recombinant proteins, and synthetic small molecules,
wherein the agent is covalently bound to the ARRDC1 protein or fragment thereof,

wherein the microvesicle further comprises an integrin, a receptor tyrosine kinase, a G-protein coupled receptor, a membrane-bound
immunoglobulin, or a protein selected from the group consisting of AHCYL2, AIP, AKR7L, AP1B1, AP1M2, C8orf30A, CASK, CNNM4,
CPM, CSNK1A1, CSNK1A1L, CSNK2A1, CXADR, EFCAB4B, EIF4B, ENAH, EPB41L5, ERBB2IP, EXOC1, EXOC2, EXOC7, EXOC8, FAM102A, FAM83F,
FAM84B, FERMT2, FNBP1L, GALNT7, GRB7, GRB7, ILK-2, INPP5A, IP:IPI00328587.4, IP:IPI00719051.3, ITCH, KIAA0174, KIAA1244, KIAA1522,
KIAA1598, KIF13B, LASP1, LNPEP, LRRC1, LSS, MAPK3, MARK2, MLPH, MON2, MTOR, MTSS1, MYO10, MYO18A, NF2, NOTCH2, OCLN, PARVA,
PIK3R2, PKM2, PPCS, PPID, PRKAG1, PSMC3, PTPRD, PVRL2, QARS, RAD23B, RHPN2, SH3GL1, SNTB2, SPAG1, SPINT1, SRM, STARD10, STUB1,
STX16, SYTL1, TLN2, TNS3, TRIM3, TUBB2C, TWF1, USP5, VAV2, VAV3, XPOT, YARS, ZDHHC5, and ZYX.

US Pat. No. 9,595,685

NANOSCALE WIRES, NANOSCALE WIRE FET DEVICES, AND NANOTUBE-ELECTRONIC HYBRID DEVICES FOR SENSING AND OTHER APPLICATIONS

President and Fellows of ...

1. A field effect transistor, comprising:
a source electrode;
a drain electrode;
a transistor channel electrically connecting the source electrode to the drain electrode wherein the transistor channel comprises
a nanoscale wire; and

a nanotube positioned such that one end of the nanotube physically contacts a side of the transistor channel.

US Pat. No. 9,428,507

COMPOUNDS FOR THE TREATMENT OF MALARIA

The Broad Institute, Inc....

1. A compound according to Formula (I):

wherein a and b are independently 0, 1, or 2;
c is 0, 1, 2, 3, or 4;
R1 is hydrogen, C1-C6 alkyl, C2-C9 heteroaryl, C3-C10 carbocyclyl C1-C6 alkyl, C6-C10 aryl C1-C6 alkyl, C2-C9 heteroaryl C1-C6 alkyl, —C(O)NR7R8, —C(O)OR9, —C(O)R10, or —S(O)2R11;

each R2 is independently hydroxyl, halogen, or —OR12;

R3 is hydrogen or C1-C6 alkyl;

R4 is hydrogen or C1-C6 alkyl;

R5 is C1-C6 alkyl, or —(CH2)nX1R13, or R5 and R6 together with the carbon and nitrogen atoms to which they are respectively attached, combine to form a 5-8-membered heterocycle;

R6 is hydrogen, C1-C6 alkyl, C1-C6 perfluoroalkyl, C3-C10 carbocyclyl C1-C6 alkyl, C6-C10 aryl C1-C6 alkyl, C2-C9 heteroaryl C1-C6 alkyl, C2-C9 heterocyclyl C1-C6 alkyl, N-protecting group, —C(O)R15, —C(O)NR16R17, or —S(O)2R18;

R7 is hydrogen or C1-C6 alkyl;

R8 is C6-C10 aryl, C2-C9 heteroaryl, C2-C9 heterocyclyl, or C3-C10 carbocyclyl;

R9 is C1-C6 alkyl or C6-C10 aryl;

R10 is C1-C6 alkyl, C6-C10 aryl, C2-C9 heterocyclyl, C6-C10 aryl C1-C6 alkyl, or C2-C9 heteroaryl C1-C6 alkyl;

R11 is C1-C6 alkyl, C6-C10 aryl, or C6-C10 aryl C1-C6 alkyl;

each R12 is C1-C6 alkyl or C1-C6 acyl;

n is 1, 2, 3, 4, 5, or 6;
X1 is absent, O, or NR14;

R13 is hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, C1-C6 perfluoroalkyl, C1-C6 acyl, C6-C10 aryl C1-C6 alkyl, an O- or N-protecting group, or R13 and R14 combine to form a 5-8-membered heterocycle;

R14 is hydrogen or C1-C6 alkyl;

R15 is C1-C6 alkyl, C1-C6 perfluoroalkyl, C1-C6 heteroalkyl, C3-C10 carbocyclyl, C2-C9 heterocyclyl, C6-C10 aryl, C6-C10 aryl C1-C6 alkyl;

R16 and R17 are independently hydrogen, C1-C6 alkyl, or C6-C10 aryl; and

R18 is C1-C6 alkyl, C1-C6 perfluoroalkyl, C3-C10 carbocyclyl, or C6-C10 aryl;

wherein the compound is not compound 12, compound 15, or any one of compounds 78-135 of Table 1,
or a pharmaceutically acceptable salt thereof.

US Pat. No. 9,127,019

CORTISTATIN ANALOGUES AND SYNTHESIS THEREOF

President and Fellows of ...

1. A compound of formula:
or a pharmaceutically acceptable salt thereof,wherein:
each of the dashed lines independently represents the presence or absence of a bond;
each instance of m and n is 1;
R1 is substituted or unsubstituted heteroaryl;

R2 is C1-C6 aliphatic;

R3 is hydrogen;

R4 is —N(RD)2; —NHC(?O)RD; —NRAC(?O)N(RD)2; or —NRDC(?O)ORD; and

RA is hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety, an aryl moiety, a heteroaryl
moiety, alkoxy, aryloxy, alkylthio, arylthio, amino, alkylamino, dialkylamino, heteroaryloxy, or heteroarylthio moiety; and

each occurrence of RD is independently hydrogen, a protecting group, aliphatic, heteroaliphatic, acyl, aryl, or heteroaryl.

US Pat. No. 9,121,307

SLIPPERY SURFACES WITH HIGH PRESSURE STABILITY, OPTICAL TRANSPARENCY, AND SELF-HEALING CHARACTERISTICS

President and Fellows of ...

1. An article having a repellant surface, the article comprising:
a substrate comprising a roughened surface having a predetermined roughness and one or more functional groups chemically attached
to the roughened surface; and

a lubricating liquid that has a chemical affinity to the substrate, as determined by an equilibrium contact angle of less
than 90°, to wet spontaneously the substrate,

the lubricating liquid wetting and adhering to the functionalized roughened surface to provided a stabilized liquid at a thickness
sufficient to form a liquid overlayer above the functionalized roughened surface,

wherein the predetermined roughness and the one or more functional groups are effective to substantially stably immobilize
the lubricating liquid in, on and over the functionalized roughened surface, without dewetting from the substrate, to form
a repellant surface.

US Pat. No. 9,115,358

MOENOMYCIN BIOSYNTHESIS-RELATED COMPOSITIONS AND METHODS OF USE THEREOF

President and Fellows of ...

1. An isolated recombinant cell expressing one or more polypeptides that comprise a moenomycin biosynthesis-related polypeptide
selected from the group consisting of: MoeA4 (SEQ ID NO: 29), MoeB4 (SEQ ID NO: 30), MoeC4 (SEQ ID NO: 28), MoeB5 (SEQ ID
NO: 27), Moe A5 (SEQ ID NO: 26), MoeD5 (SEQ ID NO: 47), MoeJ5 (SEQ ID NO: 48), MoeE5 (SEQ ID NO: 42), MoeF5 (SEQ ID NO: 36),
MoeH5 (SEQ ID NO: 37), MoeK5 (SEQ ID NO: 38), MoeM5 (SEQ ID NO: 39), MoeN5 (SEQ ID NO: 43), MoeO5 (SEQ ID NO: 44), MoeX5 (SEQ
ID NO: 46), MoeP5 (SEQ ID NO: 45), MoeR5 (SEQ ID NO: 40), MoeS5 (SEQ ID NO: 41), MoeGT1 (SEQ ID NO: 31), MoeGT2 (SEQ ID NO:
32), MoeGT3 (SEQ ID NO: 33), MoeGT4 (SEQ ID NO: 34), MoeGT5 (SEQ ID NO: 35), and variants thereof having at least about 95%
sequence identity to the corresponding natural moenomycin biosynthesis-related polypeptide, wherein the cell is selected from
the group consisting of: Streptomyces lividans TK24, E. coli, a mammalian cell, a yeast cell, and an insect cell.

US Pat. No. 9,561,544

METHODS AND DEVICES FOR SAFELY PENETRATING MATERIALS

BETH ISRAEL DEACONESS MED...

1. A drilling device comprising:
a bi-stable coupling connecting a motor to a drill chuck, the drill chuck being adapted to rotate about a longitudinal axis
as a result of a rotational force applied by the motor;

wherein the bi-stable coupling having at least two positions;
in a first position, the bi-stable coupling resists a reactive force applied along the longitudinal axis applied to the drill
chuck; and

in a second position, the bi-stable coupling does not resist a reactive force applied along the longitudinal axis applied
to the drill chuck; and

wherein the bi-stable coupling extends along the longitudinal axis having a first length while in the first position and a
second, shorter length while in the second position.

US Pat. No. 9,498,761

FLUOROCARBON EMULSION STABILIZING SURFACTANTS

Raindance Technologies, I...

1. A surfactant, comprising a block copolymer including a perfluorinated polyether (PFPE) block coupled to a polyethylene
glycol (PEG) block via an amide bond, wherein the PFPE block comprises a formula of F(CF(CF3)CF2O)x—CF(CF3)CONH—, wherein x is an integer greater than or equal to 8; and the PEG block comprises a formula of—(CnH2n O)y—or —(CnH2nO)y—CH3, wherein n is a positive integer and y is an integer greater than or equal to 10.
US Pat. No. 9,297,796

BENT NANOWIRES AND RELATED PROBING OF SPECIES

President and Fellows of ...

1. An article, comprising:
a nanoscale wire having at least one kink, wherein the nanoscale wire is a single crystal and at least a portion of a surface
of the nanoscale wire is amphiphilic.

US Pat. No. 9,541,512

MULTI-COLOR NANOSCALE IMAGING BASED ON NANOPARTICLE CATHODOLUMINESCENCE

PRESIDENT AND FELLOWS OF ...

1. A system comprising:
an electron microscope configured to generate an image of a nanoparticle sample containing a plurality of nanoparticles, by
irradiating the nanoparticle sample with electron beams;

wherein the nanoparticles comprise a plurality of spectrally distinct optical emitters configured to generate CL (cathodoluminescent)
light at respective different color channels in response to the electron beams from the electron microscope; and

a CL detecting imaging system configured to detect the CL light from the nanoparticles and to generate multi-color CL images
of the nanoparticle sample;

wherein the nanoparticles comprise nanodiamonds that contain NV (nitrogen-vacancy) color centers, and that are configured
to produce red cathodoluminescent light at a wavelength of about 620 nm.

US Pat. No. 9,518,103

OPTOGENETIC PROBES FOR MEASURING MEMBRANE POTENTIAL

President and Fellows of ...

1. A polypeptide comprising a variant having at least 80% identity to SEQ ID NO: 1, wherein the amino acid sequence of the
variant comprises at least one substitution mutation selected from the group consisting of P60S, T80S, D95H, D95Q, D106H,
and F161V, wherein the position of the at least one substitution mutation in the amino acid sequence corresponds to SEQ ID
NO:1.

US Pat. No. 9,499,521

INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS

President and Fellows of ...

1. A compound having the following structure (Ia):
or a pharmaceutically acceptable salt or tautomer thereof.

US Pat. No. 9,361,962

SOLID-STATE QUANTUM MEMORY BASED ON A NUCLEAR SPIN COUPLED TO AN ELECTRONIC SPIN

PRESIDENT AND FELLOWS OF ...

1. A system comprising:
a solid state lattice containing an electronic spin coupled to a nuclear spin;
an optical excitation configuration which is arranged to generate first optical radiation to excite the electronic spin to
emit output optical radiation without decoupling the electronic and nuclear spins;

wherein the optical excitation configuration is further arranged to generate second optical radiation of higher power than
the first optical radiation to decouple the electronic spin from the nuclear spin thereby increasing coherence time of the
nuclear spin;

a first pulse source configured to generate radio frequency (RF) excitation pulse sequences to manipulate the nuclear spin;
a second pulse source configured to generate microwave excitation pulse sequences to manipulate the electronic spin causing
a change in intensity of the output optical radiation correlated with the electronic spin and with the nuclear spin via the
coupling between the electronic spin and the nuclear spin; and

a detector configured to detect the output optical radiation correlated with the electronic spin and the nuclear spin so as
to detect a nuclear spin state of the nuclear spin.

US Pat. No. 9,418,342

METHOD AND APPARATUS FOR DETECTING MODE OF MOTION WITH PRINCIPAL COMPONENT ANALYSIS AND HIDDEN MARKOV MODEL

President and Fellows of ...

1. A method for determining a mode of motion, the method comprising:
receiving, by a processor, training data, wherein the training data comprises gait information associated with a plurality
of different modes of motion;

performing, by the processor, principal component analysis on the training data to extract principal components from the training
data;

generating, by the processor, a hidden markov model for each of a plurality of different modes of motion based upon the training
data;

receiving, by the processor, testing data comprising gait information;
transforming, by the processor, the testing data based upon the principal components;
calculating, by the processor, a likelihood of the testing data based upon each hidden markov model for each of the plurality
of different modes of motion;

determining, by the processor, the mode of motion of the testing data, wherein the mode of motion is one of the plurality
of different modes of motion for which a highest likelihood is calculated;

determining, by the processor, a most likely state path for the testing data through the hidden markov model for the mode
of motion; and

outputting, by the processor, the mode of motion that is determined when the most likely state path does not follow a disfavored
state transition of the hidden markov model for the mode of motion.

US Pat. No. 9,322,037

CAS9-FOKI FUSION PROTEINS AND USES THEREOF

President and Fellows of ...

1. A fusion protein comprising two domains:
(i) a nuclease-inactivated Cas9 (dCas9) domain comprising an amino acid sequence that is at least 90% identical to the amino
acid sequence of SEQ ID NO: 5, wherein the dCas9 comprises a D10A and/or a H840A mutation and lacks nuclease activity; and

(ii) a nuclease domain that is at least 90% identical to SEQ ID NO: 6,
wherein the two domains are separated by a peptide linker selected from the group consisting of (GGS)3, (GGS)6, SGSETPGTSESATPES (SEQ ID NO:16), SGSETPGTSESA (SEQ ID NO:17), SGSETPGTSESATPEGGSGGS (SEQ ID NO:18), VPFLLEPDNINGKTC (SEQ
ID NO:19), GSAGSAAGSGEF (SEQ ID NO:20), SIVAQLSRPDPA (SEQ ID NO:21), MKIIEQLPSA (SEQ ID NO:22), VRHKLKRVGS (SEQ ID NO:23),
GHGTGSTGSGSS (SEQ ID NO:24), MSRPDPA (SEQ ID NO:25), and GGSM (SEQ ID NO:301).

US Pat. No. 9,260,723

RNA-GUIDED HUMAN GENOME ENGINEERING

President and Fellows of ...

1. A method of integrating foreign DNA into a genomic nucleic acid sequence of a eukaryotic cell comprising providing to the
eukaryotic cell a single stranded DNA (ssDNA) donor sequence tethered to a guide RNA sequence via hybridization, wherein the
guide RNA sequence comprises a spacer sequence complementary to a target nucleic acid sequence, providing to the eukaryotic
cell a Cas9 enzyme that interacts with the guide RNA sequence and cleaves the target nucleic acid sequence in a site specific
manner, wherein the spacer sequence of the guide RNA sequence binds to the complementary target nucleic acid sequence and
the Cas9 enzyme cleaves the target nucleic acid sequence in a site specific manner; and wherein the ssDNA donor sequence is
integrated into the genomic nucleic acid sequence.

US Pat. No. 9,864,953

SYSTEMS AND METHODS FOR BAYESIAN OPTIMIZATION USING INTEGRATED ACQUISITION FUNCTIONS

President and Fellows of ...

1. A system for optimizing performance of a machine learning system, the system comprising:
at least one computer hardware processor; and
at least one non-transitory computer-readable storage medium storing processor-executable instructions that, when executed
by the at least one computer hardware processor, cause the at least one computer hardware processor to perform:

identifying at least a first set of hyper-parameter values at which to evaluate an objective function that relates hyper-parameter
values of the machine learning system to values providing a measure of performance of the machine learning system, the identifying
performed at least in part by using an integrated acquisition utility function and a probabilistic model of the objective
function, wherein the integrated acquisition utility function is obtained at least in part by integrating an initial acquisition
utility function with respect to at least one parameter of the probabilistic model;

evaluating the objective function at least at the identified first set of hyper-parameter values, at least in part by executing
the machine learning system when configured with the first set of hyper-parameter values, to obtain a corresponding first
value providing a measure of performance of the machine learning system when operated using the first set of hyper-parameter
values; and

updating the probabilistic model of the objective function using results of the evaluating to obtain an updated probabilistic
model of the objective function.

US Pat. No. 9,573,099

CONTROL OF EMULSIONS, INCLUDING MULTIPLE EMULSIONS

President and Fellows of ...

1. A method of creating an emulsion encapsulating a species, the method comprising:
providing a microfluidic device comprising a first junction of microfluidic channels comprising at least a first, second,
and third microfluidic channels in fluidic communication, the first junction in fluid communication at an interface with a
second junction of microfluidic channels comprising at least fourth, fifth, and sixth microfluidic channels in fluid communication,
each of the first, second, and third microfluidic channels having a respective cross-sectional area at the first junction
and each of the fourth, fifth, and sixth microfluidic channels having a respective cross-sectional area at a second junction,
wherein the interface has a cross-sectional area smaller than the smallest cross-sectional areas of the fourth, fifth, and
sixth microfluidic channels; and creating an emulsion encapsulating a species at the first and second junctions of microfluidic
channels.

US Pat. No. 9,353,188

MODULATORS OF PLEXIN B2 ACTIVITY

President and Fellows of ...

1. An isolated antibody or antigen binding fragment thereof that specifically binds to an Angiogenin (ANG) binding epitope
of Plexin B2, wherein the ANG binding epitope consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID
NO: 3.

US Pat. No. 9,347,829

INTEGRATED NANOBEAM CAVITY ARRAY SPECTROMETER

President and Fellows of ...

1. A method for spectrally separating incoming signals using arrays of optical micro-cavities, and mapping the spectrally
separated signals to spatially separated wave-guiding devices or imaging devices, the method comprising the steps of:
coupling an optical signal to be analyzed from an optical fiber into an input waveguide;
splitting said optical signal to be analyzed;
inputting said split optical signal into a plurality of micro-cavities, wherein each of said micro-cavities comprises a silicon
ridge waveguide having a plurality of holes patterned along the waveguide, wherein holes in the center of the cavity are largest
and the holes taper monotonically to both ends;

using constructive interference in said plurality of micro-cavities to produce optical resonance to spectrally separate incoming
signals; and

transferring said separated signals to different channels.

US Pat. No. 9,335,539

PIXEL DEVICE AND DISPLAY USING LIQUID INK AND ELASTOMERS

President and Fellows of ...

1. A flexible display comprising:
a fluid-filled cavity;
a dielectric elastomer, coupled to the cavity; and
electrodes attached to opposing sides of the dielectric elastomer, wherein an electric potential applied across the electrodes
causes the dielectric elastomer to deform, thereby causing the fluid to flow, thereby altering an optical property of the
display.

US Pat. No. 9,243,038

MACROCYCLIC INSULIN-DEGRADING ENZYME (IDE) INHIBITORS AND USES THEREOF

President and Fellows of ...

1. A compound of Formula (V):
or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, polymorph, tautomer, or isotopically enriched form
thereof,wherein:
is a single or double C—C bond, wherein when is a double C—C bond, then indicates that the adjacent C?C double bond is in a cis or trans configuration;
R1 is —CH2CH2CH2CH2—NH2;

R2 is hydrogen; halogen; substituted or unsubstituted aliphatic; or substituted or unsubstituted heteroaliphatic;

R5 is substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl;
substituted or unsubstituted heteroaryl; substituted or unsubstituted amino; —C(?O)—N(RJ)2; —C(?O)—ORJ; —C(?O)—SRJ; or —CH2—C(?O)N(RJ)2, wherein each occurrence of RJ is independently hydrogen; a protecting group; substituted or unsubstituted aliphatic; substituted or unsubstituted heteroaliphatic;
substituted or unsubstituted acyl; substituted or unsubstituted aryl; or substituted or unsubstituted heteroaryl; or two RJ groups are joined to form a substituted or unsubstituted heterocyclic group;

each instance of RE, RF, RG, RH, and RI is independently hydrogen; a nitrogen protecting group; substituted or unsubstituted aliphatic; or substituted or unsubstituted
heteroaliphatic;

n is 0 or an integer between 1 and 10, inclusive; and
m is an integer between 1 and 5, inclusive.

US Pat. No. 9,512,465

METHODS AND COMPOSITIONS FOR LABELING NUCLEIC ACIDS

Life Technologies Corpora...

1. A method of differentially labeling DNA, comprising steps of:
contacting a first cell with an effective amount of a first nucleoside analogue that comprises a first azide group such that
the nucleoside analogue is incorporated into DNA of the first cell;

contacting a second cell with an effective amount of a second nucleoside analogue that comprises a second azide group such
that the nucleoside analogue is incorporated into DNA of the second cell;

contacting the first cell with a first reagent comprising a first label attached to a first substituted triarylphoshine, such
that a Staudinger ligation occurs between the first azide and first substituted triarylphosphine; and

contacting the second cell with a second reagent comprising a second label attached to a second substituted triarylphosphine,
such that a Staudinger ligation occurs between the second azide and second substituted triarylphosphine.

US Pat. No. 9,476,097

STRUCTURAL MUTATIONS IN TITIN CAUSE DILATED CARDIOMYOPATHY

President and Fellows of ...

1. A method of treating a subject for dilated cardiomyopathy (DCM), comprising:
a. Selecting a subject in need of treatment for DCM using an assay comprising:
i. contacting a nucleic acid sample obtained from a subject with a probe, wherein the probe is capable of detecting a mutation
resulting in a truncated TITIN polypeptide;

ii. detecting the presence of the mutation in the nucleic acid sample, and
b. administering a treatment for DCM if at least one mutation is detected in (ii);
wherein the mutation is selected from the group consisting of 6247_6247delG, 12745C>T, 14470_14471insCACACTCCATA (SEQ ID NO:
722), 19183_19183delG, 23798_23810delGTCAAGATATCTG (SEQ ID NO: 723), 38621_38622insA, 44336_44336delA, 45322_45322delT, 49077G>A,
51883C>T, 52408C>T, 53145_53146insG, 53347G>T, 53935_53935delC, 56367T>A, 56572C>T, 56953C>T, 58678C>T, 59530C>T, 61046_61046delC,
65867_65867delA, 67057_67063delGCATATGinsTA, 67745_67745delT, 72178_72179insT, 72723_72739delinsAGA, 77065C>T, 79896G>A, 80845C>T,
81046A>T, 81440G>A, 81536_81537delCT, 82701C>A, 84977_84980delATTA, 87953G>A, 88242C>T, 88528G>T, 89177_89181delAAATT, 90241C>T,
91042_91042delA, 91537_91538insA, 94111A>T, 95522C>A, 30476-1G>A, 34186+1G>T, 35635G>C, 35635+1G>A, 44725+2delT, 48364+1G>T,
50346_+3A>G, 54422-5T>A, 54704-1G>A, 55003+1G>A, 62425+5G>A, 63405A>G, 64489+1G>A, 81898+2T>A, 92569+1G>C, and any combination
thereof, wherein the mutation location is determined based upon the wildtype TTN sequence having a nucleic acid sequence set
forth in SEQ ID NO: 1.

US Pat. No. 9,434,779

GROWTH DIFFERENTIATION FACTOR 11 (GDF-11) FOR TREATMENT OF DIASTOLIC HEART FAILURE

President and Fellows of ...

1. A method of treating an age-related cardiac hypertrophy, the method comprising administering to a mammalian subject a composition
comprising a mammalian GDF11 polypeptide, whereby the composition increases the level of Growth Differentiation Factor 11
(GDF11) polypeptide in the subject; and wherein the composition is administered intraperitoneally; intravenously; subcutaneously:
intra-arterially; or intra-coronary arterially.
US Pat. No. 9,390,971

SELF-ALIGNED BARRIER AND CAPPING LAYERS FOR INTERCONNECTS

President and Fellows of ...

1. A process for forming an integrated circuit interconnect structure, said process comprising:
a) providing a partially-completed interconnect structure having one or more vias and trenches, said vias and trenches comprising
sidewalls defined by one or more electrically insulating materials and electrically conductive copper-containing bottom regions;

b) depositing a layer comprising a nitride of a metal selected from the group consisting of manganese, chromium and vanadium
on the partially-completed interconnect structure;

c) depositing copper within said one or more vias and trenches.

US Pat. No. 9,320,815

COMPOUNDS AND METHODS FOR ENZYME-MEDIATED TUMOR IMAGING AND THERAPY

President and Fellows of ...

1. A compound represented by the formula

in which
R1 is H, COOH, amino, mono- or di(C1-C6alkyl)amino, C1-C8alkyl, C2-C8alkenyl, C3-C8cycloalkyl, aryl, halogen, C1-C8alkoxy, nitro, or cyano; or R1 is a radionuclide or a moiety complexed with a radionuclide; and

R2 is, independently for each occurrence, H, hydroxy, COOH, amino, mono- or di(C1-C6alkyl)amino, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C3-C8cycloalkyl, aryl, halogen, C1-C8alkoxy, nitro, cyano, or a radionuclide or a moiety containing, or capable of complexing with, a radionuclide;

or a pharmaceutically acceptable salt thereof.
wherein the radionuclide is 10B, 11C, 13N, 15O, 32P, 33P, 212Bi, 123I, 131I, 111In, 99mTc, 124I, 18F, 90Y, 211At, or 213Bi,

and wherein at least one occurrence of R1 or R2 is a radionuclide or moiety complexed with a radionuclide.

US Pat. No. 9,274,097

MOLECULAR CHARACTERIZATION WITH MOLECULAR SPEED CONTROL

President and Fellows of ...

1. A method for controlling translocation of an electrically charged molecule through a nanopore comprising:
applying a molecular translocation voltage across a nanopore between a molecular inlet entrance at the nanopore and a molecular
outlet exit at the nanopore;

applying to at least one electrically conducting probe disposed at the nanopore a first voltage bias with respect to the translocation
voltage, while the translocation voltage is applied across the nanopore, to slow progression of a molecule through the nanopore
between the molecular inlet and the molecular outlet;

electrically detecting the molecule at the nanopore while the first voltage bias is applied; and
applying to at least one electrically conducting probe disposed at the nanopore a second voltage bias will respect to the
translocation voltage, while the translocation voltage is applied across the nanopore, to cause the molecule to proceed through
the nanopore between the molecular inlet entrance and the molecular outlet exit at the nanopore.

US Pat. No. 9,150,626

PROTEIN SURFACE REMODELING

President and Fellows of ...

1. A method of improving the stability of a protein of interest, the method comprising steps of:
(1) identifying non-conserved surface residues of a protein of interest by comparing the amino acid sequence of the protein
with at least one other amino acid sequence of the protein from the same protein family or a different species, wherein a
residue is non-conserved if less than or equal to 50% of the amino acid sequences have the same amino acid sequence in a particular
position; and

(2) replacing a plurality of non-conserved, surface residues identified in step (1) with a natural amino acid residue that
is positively charged at physiological pH, whereby the method creates a modified protein of interest having a theoretical
net charge of at least about +10 at physiological pH as compared to the theoretical net charge of the original protein of
interest.

US Pat. No. 9,102,521

NANOSENSORS AND RELATED TECHNOLOGIES

President and Fellows of ...

1. An article, comprising:
a nanoscale wire comprising a first portion and a second portion laterally defined along the length of the nanoscale wire,
the first portion consisting essentially of a single crystal of a transition metal silicide compound, the compound being stoichiometric,
and the second portion comprising a semiconductor, having a length of less than 100 nm, and having immobilized relative thereto
a binding partner of an analyte, wherein the first portion is free of the binding partner.

US Pat. No. 9,267,127

EVOLUTION OF BOND-FORMING ENZYMES

President and Fellows of ...

1. A sortase comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of Staphylococcus aureus (S. aureus) Sortase A as provided as SEQ ID NO: 1 or to amino acid residues 1-150 of SEQ ID NO: 21, wherein the amino acid sequence
of the sortase comprises two or more mutations selected from the group consisting of P94S, P94R, E106G, F122Y, K154R, D160N,
D165A, G174S, K190E, and K196T.

US Pat. No. 9,257,936

SYSTEM AND METHOD FOR EFFICIENT DRIVE OF CAPACITIVE ACTUATORS WITH VOLTAGE AMPLIFICATION

President and Fellows of ...

1. A circuit for driving a plurality of capacitive actuators, comprising:
a low-voltage side comprising:
first and second pairs of low-side switches, said first pair of comprising switches Q1 and Q3 connected in series across said input voltage and said second pair comprising switches Q2 and Q4 connected in series across said input voltage;

low-side control logic connected to said low-side switches Q1, Q2, Q3 and Q4 for controlling said low-side switches Q1, Q2, Q3 and Q4; and

a flyback transformer having a primary winding connected on a first end between said switches Q1 and Q3 and connected on a second end between said switches Q2 and Q4;

a high-voltage side comprising:
a switch Q5 connected between a first end of a secondary winding of said flyback transformer and a ground;

a capacitive load CA0;

a bidirectional switch QA0 connected in series with said capacitive load CA0, wherein when said bidirectional switch QA0 is closed said capacitive load CA0 is connected between said first end of said secondary winding of said flyback transformer and a ground;

a switch Q6 connected between a second end of a secondary winding of said flyback transformer and a ground;

a capacitive load CB0; and

a bidirectional switch QB0 connected in series with said capacitive load CB0, wherein when said bidirectional switch QB0 is closed said capacitive load CB0 is connected between said second end of said secondary winding of said flyback transformer and a ground;

high-side control logic connected to said switches Q5, Q6, QA0 and QB0 for controlling said switches Q5, Q6, QA0 and QB0.

US Pat. No. 9,241,916

COGNITIVE PERFORMANCE WITH SIRTUIN ACTIVATORS

President and Fellows of ...

1. A method for improving cognitive performance in a mammalian subject, comprising
(i) determining the cognitive performance of a mammalian subject;
(ii) comparing the cognitive performance of the mammalian subject to a control value; and
(iii) administering to the mammalian subject a SIRT1-activating agent if the cognitive performance of the mammalian subject
is lower than the control value, wherein the SIRT1-activating agent is a non-naturally occurring compound, and wherein the
SIRT1-activating agent is not a stilbene, flavone or flavonoid.

US Pat. No. 9,192,933

MICROFLUIDIC, ELECTROCHEMICAL DEVICES

President and Fellows of ...

1. A microfluidic, electrochemical analysis device comprising:
plural porous, hydrophilic layers, respectively separated by a fluid impermeable layer defining one or more openings in alignment
with at least a portion of one or more hydrophilic channels within a hydrophilic layer to permit vertical fluidic communication
through said fluid impermeable layer between said hydrophilic layers, wherein a porous, hydrophilic layer comprises a fluid
sample deposition region and a patterned, fluid impermeable boundary that substantially permeates the thickness of the hydrophilic
layer and defines the one or more hydrophilic channels therewithin in fluidic communication with said deposition region which
permit fluidic flow within the one or more channels; and

an electrode assembly comprising one or more electrodes in fluidic communication with said deposition region through the one
or more hydrophilic channels, wherein said electrode assembly is disposed in fluidic communication with the one or more hydrophilic
channels on one hydrophilic layer and a sample deposition region disposed on another hydrophilic layer.

US Pat. No. 9,116,148

FLUID DELIVERY SYSTEM AND METHOD

President and Fellows of ...

1. A method comprising:
providing a first fluid and a second fluid maintained separately from each other by a third fluid in a common, sealed vessel,
wherein the third fluid is adjacent to and substantially immiscible with the first and second fluids;

unsealing the vessel;
transferring the first, third and second fluids in series from the vessel to an analysis region; and
avoiding contact between at least portions of the first and second fluids, at least until after the fluids have been applied
to the analysis region.

US Pat. No. 9,068,168

BOUNDARY CONDITIONS FOR THE ARRANGEMENT OF CELLS AND TISSUES

President and Fellows of ...

1. An in vitro method of forming a mature muscle tissue, comprising:
(a) providing a medium or substrate;
(b) providing a boundary condition associated with the medium or substrate, wherein said boundary condition directs the alignment
and development of dissociated muscle cells to form a mature muscle tissue;

(c) providing the dissociated muscle cells to the medium or substrate, wherein the muscle cells arrange based upon the boundary
condition; and

(d) culturing the muscle cells to form a mature muscle tissue,
wherein the boundary condition directs the movement and growth of the muscle cells upon interaction with the boundary condition
as compared to interaction with the medium or substrate alone such that substantially all of the muscle cells and sarcomeres
within the muscle cells are spatially anisotropic in at least one direction and substantially all of the muscle cells coordinately
contract, thereby forming a mature muscle tissue.

US Pat. No. 9,526,702

VACCINE NANOTECHNOLOGY

Massachusetts Institute o...

1. Nanoparticles having a geometric diameter of between greater than 60 nm and less than 250 nm, and formed of one or more
polymers selected from the group consisting of polyesters, polyhydroxacids, poly(orthoesters); polyanhydrides, polyalkylene
oxides, and copolymers thereof,
wherein the nanoparticles selectively target the subcapsular macrophages and dendritic cells in the draining lymph nodes,
and

wherein the nanoparticles comprise
a dendritic cell immunomodulatory agent selected from the group consisting of toll-like receptor agonists, CD40 agonists,
and agents which promote dendritic cell maturation; and

a T cell peptide antigen for processing by dendritic cells and presentation with major histocompatibility complex (MHC) to
T cells.

US Pat. No. 9,519,650

SYSTEMS AND METHODS FOR GENETIC DATA COMPRESSION

PRESIDENT AND FELLOWS OF ...

1. A computer-implemented method of compressing, for a plurality of subjects, genetic data corresponding to at least one bi-allelic
marker having at least one minor allele frequency associated therewith, the method utilizing at least two compression algorithms
and comprising:
for each of the at least one bi-allelic marker,
using a computer processor to (i) compute storage requirements associated with each of the at least two compression algorithms,
the storage requirement of at least one of the compression algorithms depending, at least in part, on the minor allele frequency
associated with the marker, and (ii) compress the genetic data for the marker using only the compression algorithm having
the lowest storage requirement associated therewith, and

storing the compressed genetic data; and
using the computer processor, analyzing the compressed genetic data without decompression,
wherein the at least two compression algorithms are selected from (i) a binary-encoding algorithm, (ii) an algorithm wherein
total numbers and unique indices of (a) all subjects having a rare homozygous genotype for a marker, (b) all subjects having
a heterozygous genotype for the marker, and (c) all subjects having an unknown genotype for the marker are expressed in binary
numbers, and (iii) an algorithm wherein the total numbers and unique indices of (a) all subjects having a rare homozygous
genotype for a marker and (b) all subjects having an unknown genotype for the marker are expressed in binary numbers, and
the unique indices of all subjects having a heterozygous genotype for the marker are expressed in a single n-digit number,
where n is the number of subjects.

US Pat. No. 9,498,759

COMPARTMENTALIZED SCREENING BY MICROFLUIDIC CONTROL

President and Fellows of ...

1. A method for identifying a compound(s) in a repertoire of compounds, which compound(s) possess(es) a desired activity,
comprising the steps of:
(a) obtaining the repertoire of compounds in an aqueous fluid;
(b) forming a plurality of microcapsules by partitioning the aqueous fluid with two counter propagating streams of immiscible
fluid as the aqueous fluid is flowing through a microfluidic channel and passes through a constriction, wherein each microcapsule
comprises a subset of the repertoire of compounds; and

(c) identifying at least one compound in at least one of the microcapsules possessing the desired activity from the repertoire
of compounds, wherein one or both of the steps (b) and (c) are performed under microfluidic control.

US Pat. No. 9,433,698

HIGH STRENGTH CHITIN COMPOSITE MATERIAL AND METHOD OF MAKING

President and Fellows of ...

1. A composite laminate material comprising a carbohydrate based layer and a protein based layer, wherein carbohydrate to
protein are present in a ratio in the range of 1:1.5 to 1:2.5, where the ratio is based on dry weight or moles of carbohydrate
and protein, and wherein chitosan is the carbohydrate in the carbohydrate based layer and silk fibroin is the protein in the
protein based layer.
US Pat. No. 9,383,350

ENGINEERED CELL GROWTH ON POLYMERIC FILMS AND BIOTECHNOLOGICAL APPLICATION THEREOF

President and Fellows of ...

1. A method for measuring contractility of a functional muscle tissue, comprising:
providing a free-standing muscle thin film, said free-standing muscle thin film comprising a flexible polymer layer, a spatially
micro-patterned engineered surface chemistry deposited on the flexible polymer layer, and a functional muscle tissue;

attaching an end of the free-standing muscle thin film to a mounting structure;
applying a stimulus to cause the functional muscle tissue to contract; and
measuring the displacement of the muscle thin film when the functional muscle tissue contracts in response to the stimulus,
wherein the free-standing thin film is fabricated by
providing a base layer;
coating a sacrificial polymer layer on the base layer;
coating a flexible polymer layer that is more flexible than the base layer on the sacrificial polymer layer;
depositing a spatially micro-patterned engineered surface chemistry on the flexible polymer layer, wherein said spatially
micro-patterned engineered surface chemistry allows for the alignment of muscle cells such that a functional muscle tissue
is formed;

seeding muscle cells on the flexible polymer layer comprising the spatially micro-patterned engineered surface chemistry;
culturing the muscle cells to form a functional muscle tissue; and
releasing the flexible polymer layer from the base layer to produce the free-standing muscle thin film,
thereby measuring the contractility of the functional muscle tissue.
US Pat. No. 9,345,696

METHODS FOR TREATING NICOTINIC ACETYLCHOLINE RECEPTOR ASSOCIATED DISEASES

President and Fellows of ...

1. A method for treating an 8- to 17-year-old human subject having amblyopia, the method comprising orally administering a
therapeutically effective amount of donepezil to an 8- to 17-year-old human subject having amblyopia, thereby treating the
subject.
US Pat. No. 9,228,185

MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES

PRESIDENT AND FELLOWS OF ...

1. A method of treatment of a hemoglobinopathy in a subject comprising administering an effective amount of a composition
comprising an inhibitor of BCL11A, wherein the inhibitor of BCL11A is a nucleic acid that inhibits the expression of BCL11A
and hybridizes to BCL11A, and whereby fetal hemoglobin expression is increased in the subject relative to prior to the administration.
US Pat. No. 9,046,483

CHARACTERIZATION OF INDIVIDUAL POLYMER MOLECULES BASED ON MONOMER-INTERFACE INTERACTIONS

President and Fellows of ...

1. A method comprising:
providing a surface containing a channel of a dimension sufficient to allow sequential monomer-by-monomer passage of a single-stranded
polynucleic acid, but not of a double-stranded polynucleic acid;

providing a probe polynucleic acid which is capable of hybridising to an analyte polynucleic acid;
introducing the probe polynucleic acid to a sample suspected of containing the analyte polynucleic acid;
applying a voltage across the channel to drive the probe polynucleic acid to the channel so that the probe polynucleic acid
enters the channel and to hold the probe polynucleic acid adjacent to the channel for the time sufficient for the probe and
the analyte polynucleic acids to undergo strand separation; and

monitoring the passage of the probe polynucleic acid through the channel to determine the presence of hybridized polynucleic
acid.

US Pat. No. 9,844,756

POLYETHERSULFONE FILTRATION MEMBRANE

PRESIDENT AND FELLOWS OF ...

13. A filtration membrane comprising: (a) a polymer selected from the group consisting of polyethersulfone, polysulfone, and
any combinations thereof; and (b) a dopant, wherein the dopant is sodium hexametaphosphate (SHMP).

US Pat. No. 9,458,189

LIGATION OF STAPLED POLYPEPTIDES

President and Fellows of ...

1. A method of preparing a stabilized, non-immunogenic, and folded protein comprising a stitched ?-helical peptide segment,
the method comprising steps of:
providing a stitched ?-helical peptide segment, wherein the stitched ?-helical peptide segment is of formula:
wherein
each instance of K, L1, L2, and M, is, independently, a bond, cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkylene; cyclic
or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; cyclic or acyclic, branched or unbranched, substituted
or unsubstituted alkynylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkylene; cyclic
or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; cyclic or acyclic, branched or unbranched,
substituted or unsubstituted heteroalkynylene; substituted or unsubstituted arylene; substituted or unsubstituted heteroarylene;
or substituted or unsubstituted acylene;

each instance of Ra is, independently, hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or
acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted
or unsubstituted heteroaryl; cyclic or acyclic, substituted or unsubstituted acyl; or Ra is a suitable amino protecting group;

each instance of Rb is, independently, a suitable amino acid side chain; hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted
aliphatic; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted
aryl; substituted or unsubstituted heteroaryl; cyclic or acyclic, substituted or unsubstituted acyl; substituted or unsubstituted
hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; cyano; isocyano; halo; or nitro;

each instance of Re is, independently, —RE, —ORE, —N(RE)2, or —SRE, wherein each instance of RE is, independently, hydrogen, cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or
acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted
or unsubstituted heteroaryl; substituted or unsubstituted acyl; a resin; a suitable hydroxyl, amino, or thiol protecting group;
or two RE groups together form a substituted or unsubstituted 5-to 6-membered heterocyclic or heteroaromatic ring;

each instance of Rf is, independently, hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or
acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted
or unsubstituted heteroaryl; substituted or unsubstituted acyl; a resin; a suitable amino protecting group; a label optionally
joined by a linker, wherein the linker is selected from cyclic or acyclic, branched or unbranched, substituted or unsubstituted
alkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted alkenylene; cyclic or acyclic, branched
or unbranched, substituted or unsubstituted alkynylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted
heteroalkylene; cyclic or acyclic, branched or unbranched, substituted or unsubstituted heteroalkenylene; cyclic or acyclic,
branched or unbranched, substituted or unsubstituted heteroalkynylene; substituted or unsubstituted arylene; substituted or
unsubstituted heteroarylene; or substituted or unsubstituted acylene; or Rf and Ra together form a substituted or unsubstituted 5- to 6-membered heterocyclic or heteroaromatic ring;

each instance of RKL, RLL, and RLM, is, independently, hydrogen; cyclic or acyclic, branched or unbranched, substituted or unsubstituted aliphatic; cyclic or
acyclic, branched or unbranched, substituted or unsubstituted heteroaliphatic; substituted or unsubstituted aryl; substituted
or unsubstituted heteroaryl; substituted or unsubstituted acyl; substituted or unsubstituted hydroxyl; substituted or unsubstituted
thiol; substituted or unsubstituted amino; azido; cyano; isocyano; halo; nitro;

or two adjacent RKL groups are joined to form a substituted or unsubstituted 5- to 8-membered cycloaliphatic ring; substituted or unsubstituted
5- to 8-membered cycloheteroaliphatic ring; substituted or unsubstituted aryl ring; or substituted or unsubstituted heteroaryl
ring; two adjacent RLL groups are joined to form a substituted or unsubstituted 5- to 8-membered cycloaliphatic ring; substituted or unsubstituted
5- to 8-membered cycloheteroaliphatic ring; substituted or unsubstituted aryl ring; or substituted or unsubstituted heteroaryl
ring; or two adjacent RLM groups are joined to form a substituted or unsubstituted 5- to 8-membered cycloaliphatic ring; substituted or unsubstituted
5- to 8-membered cycloheteroaliphatic ring; substituted or unsubstituted aryl ring; or substituted or unsubstituted heteroaryl
ring;

each instance of XAA is, independently, a natural or unnatural amino acid;

each instance of y and z is, independently, an integer between 2 to 6;
each instance of j is, independently, an integer between 1 to 10;
each instance of p is, independently, an integer between 0 to 10;
each instance of s and t is, independently, an integer between 0 and 100;
each instance of u, v, and q, is, independently, an integer between 0 to 2; and wherein
corresponds to a single or double bond;
providing a second protein to which the stitched ?-helical peptide segment is to be ligated, wherein the second protein is
produced recombinantly or purified from a natural source; and

ligating the stitched ?-helical peptide segment to the second protein.
US Pat. No. 9,387,276

INTERPENETRATING NETWORKS WITH COVALENT AND IONIC CROSSLINKS

President and Fellows of ...

1. A composition comprising a self-healing interpenetrating networks hydrogel comprising a first network and a second network,
wherein said first network comprises covalent crosslinks and said second network comprises ionic or physical crosslinks, wherein
said first network comprises a polymer selected from the group consisting of polyacrylamide, poly(vinyl alcohol), poly(ethylene
oxide) and its copolymers, polyethylene glycol (PEG), methacrylated PEG, and polyphosphazene; said second network comprises
an alginate polymer; wherein the Young's modulus of the hydrogel is at least 10.0 kPa, wherein said interpenetrating networks
hydrogel comprises a stretch value (?) of about 21.

US Pat. No. 9,317,473

SCALABLE ROOM TEMPERATURE QUANTUM INFORMATION PROCESSOR

PRESIDENT AND FELLOWS OF ...

1. A quantum information processor, comprising: a plurality of quantum registers, each quantum register containing at least
one nuclear spin and at least one electronic spin; wherein at least some of the quantum registers are coherently coupled to
each other by a dark spin chain;
wherein quantum information can be optically read out from each quantum register and optically initialized at each quantum
register, and moved from one quantum register to another through the dark spin chain;

wherein the quantum registers are spatially separated from each other by a distance sufficient to permit individual optical
initialization and readout; and

wherein the quantum information processor has a scalable architecture that permits simultaneous single- and two-qubit gate
operations to be performed in parallel at room temperature, the scalable architecture comprising:

an array of super-plaquettes, each super-plaquette including a two dimensional lattice of individually optically addressable
plaquettes coupled to each other through dark spin chains, each plaquette containing a single quantum register;

wherein each super-plaquette is separately controllable by confined microwave fields so as to permit parallel operations;
and wherein the quantum information is movable between the boundaries of different super-plaquettes within the array by localized
microwave fields of a dual super-plaquette lattice.

US Pat. No. 9,304,132

MOLECULAR DELIVERY WITH NANOWIRES

President and Fellows of ...

1. A system comprising:
a substrate having a surface;
a plurality of nanowires attached to the surface;
a plurality of cells of a first cell type or a second cell type penetrated by at least one nanowire of the plurality of nanowires;
and

a plurality of molecules to be delivered to the plurality of cells,
wherein at least one of the nanowires further comprises a surface layer of a silicon-containing material, a first silane linker
covalently bound thereto, and a first molecule of the plurality of molecules electrostatically bound to the first silane linker,

wherein at least one cell of the plurality of cells penetrated by the at least one nanowire of the plurality of nanowires
further contains at least some of the first molecule within the cytoplasm and not electrostatically bound to the first silane
linker,

wherein the plurality of nanowires has a diameter of less than 200 nm, a length of 2.5-5 ?m, and a density of 0.5-5 nanowires/?m2 configured for high delivery efficiency to the first cell type or a diameter of less than 200 nm, a length of 0.5-2.5 ?m,
and a density of 0.01-10 nanowires/?m2 configured for high delivery efficiency to the second cell type,

wherein the first cell type is different from the second cell type, and
wherein a second molecule of the plurality of molecules is attached to a second silane linker, the second molecule being different
from the first molecule, wherein the first molecule and the second molecule are connected to the same nanowire via the respective
silane linkers.

US Pat. No. 9,205,420

NANOSTRUCTURES, SYSTEMS, AND METHODS FOR PHOTOCATALYSIS

President and Fellows of ...

1. A nanostructure, comprising:
a first region comprising a first material that catalyzes the formation of O2 from water; and

a second region comprising a second material that catalyzes a reduction reaction,
the first and second regions comprising semiconductors,
wherein the first region comprises a first type of semiconductor material and the second region comprises a second type of
semiconductor material,

and wherein the first type of semiconductor material and the second type of semiconductor material comprise the same or different
doped iron oxides.

US Pat. No. 9,132,210

SCAFFOLDS FOR CELL TRANSPLANTATION

President and Fellows of ...

1. A cancer vaccine device comprising a scaffold composition comprising a polymer matrix and having open, interconnected macropores;
a granulocyte-macrophage colony stimulating factor (GM-CSF) that recruits immune cells selected from macrophages, T-cells,
B-cells, NK cells, and dendritic cells;

a tumor antigen; and
an immune response-promoting bioactive factor comprising an oligonucleotide, wherein the GM-CSF, the tumor antigen, or the
immune response-promoting bioactive factor is incorporated into or coated onto said scaffold composition, wherein said device
further comprises an extracellular matrix (ECM) component, and wherein the ECM component comprises an arginine-glycine-aspartate
(RGD) sequence.

US Pat. No. 9,790,490

CRISPR ENZYMES AND SYSTEMS

The Broad Institute Inc.,...

1. An engineered, non-naturally occurring system comprising
a) a Cpf1 effector protein, and
b) at least one engineered guide polynucleotide designed to form a complex with the Cpf1effector protein and comprising a
guide sequence, wherein the guide sequence is designed to hybridize with a target sequence in a eukaryotic cell; and

wherein the system lacks a tracr sequence, the engineered guide polynucleotide and Cpf1 effector protein do not naturally
occur together, and a complex of the engineered guide polynucleotide and Cpf1 effector protein does not naturally occur.

US Pat. No. 9,598,685

ENGINEERED BOTULINUM NEUROTOXIN

PRESIDENT AND FELLOWS OF ...

1. A polypeptide comprising a modified receptor binding domain of Clostridial botulinum serotype B (B-Hc) comprising an amino acid substitution mutation at the amino acid position E1191 of the polypeptide of SEQ ID NO: 4 with
M, Q, C, V, Y, T or I, wherein the substitution mutation produces enhanced binding of the modified B-Hc to human SytII as compared to an identical molecule lacking the substitution mutation.
US Pat. No. 9,541,546

METHOD OF PROMOTING EXCITATORY SYNAPSE FORMATION WITH AN ANTI-EPHEXIN5 PHOSPHO-Y361 ANTIBODY

President and Fellows of ...

1. A method of promoting spine/excitatory synapse formation, the method comprising: contacting a neuron with an anti-Ephexin5
antibody, wherein the anti-Ephexin5 antibody is anti-Ephexin5 phospho-Y361 (?-p361) antibody.

US Pat. No. 9,492,578

RECONFIGURABLE SURFACES FOR INFORMATION SECURITY AND PROTECTION OF PHYSICAL BIOMETRICS

President and Fellows of ...

1. A method of removing imprinted biometrics information from surfaces comprising:
providing a biometric information recording surface comprising a plurality of raised structures,
reproducing a biometric information on the plurality of raised structures by applying a pressure from a part of a body containing
the biometric information to the biometric information recording surface, and

removing the biometric information by applying a liquid to the plurality of raised structures without a need of applying an
external physical contact.

US Pat. No. 9,457,128

SCAFFOLDS COMPRISING NANOELECTRONIC COMPONENTS FOR CELLS, TISSUES, AND OTHER APPLICATIONS

President and Fellows of ...

1. An article, comprising:
a cell scaffold comprising semiconductor nanoscale wires and one or more polymeric constructs, wherein at least some of the
nanoscale wires form a portion of an electrical circuit that extends externally of the cell scaffold and wherein at least
one of the one or more polymeric constructs comprises a photoresist.

US Pat. No. 9,239,334

FATTY ACID C16: 1N7-PALMITOLEATE A LIPOKINE AND BIOMARKER FOR METABOLIC STATUS

PRESIDENT AND FELLOWS OF ...

1. A method of improving glycemic control/glucose metabolism in a subject in need thereof, comprising the step of administering
a pharmaceutical composition or nutraceutical comprising at least 75% w/v C16:1 n7-palmitoleate; wherein said administering
of C16:1 n7-palmitoleate is repeated or continued until a serum concentration ranging from about 12.5 ?M to about 17.5 ?M
C16:1 n7-palmitoleate is achieved, and wherein the administration of C16:1 n7-palmitoleate has at least one of the following
activities: reduces the impact of lipid-enriched diet on lipid metabolism and lipid composition; improves insulin sensitivity;
enhances insulin signaling in muscle tissue; regulates insulin actions in peripheral tissues; rescues diet-induced reduction
in insulin-stimulated AKT phosphorylation; potentiates the proximal insulin-signaling pathway, wherein said potentiation is
one of activation of insulin receptor, or phosphorylation of insulin receptor substrate 1, 2 protein kinase AKT in liver;
decreases the expression of lipogenic genes in liver, including SCD-1, fatty acid synthase (FAS), and/or fatty acid elongase
6 (ELOVL6).
US Pat. No. 9,175,340

REACTIVITY-DEPENDENT AND INTERACTION-DEPENDENT PCR

President and Fellows of ...

1. A method for interaction-dependent polymerase chain reaction, comprising:
(i) providing a nucleic acid template, wherein the nucleic acid template comprises:
a first primer hybridization site,
optionally, a sequence tag,
a second primer hybridization site, and
a candidate ligand;
(ii) contacting the nucleic acid template with a first primer, wherein the first primer comprises:
a sequence complementary to the first primer hybridization site,
a third primer hybridization site, and
a target molecule;
(iii) incubating the nucleic acid template contacted with the first primer under conditions suitable for the candidate ligand
to bind to the target molecule with a KD<10?6;

(iv) incubating the nucleic acid template contacted with the first primer under conditions suitable for bound first primer
to hybridize with the first primer hybridization site of the nucleic acid template it is bound to and for primer extension,
and not allowing for efficient primer site hybridization and primer extension of the first primer not connected to the nucleic
acid template by an interaction characterized by a KD<10?6;

(v) contacting the nucleic acid template contacted with the first primer with a PCR primer complementary to the second primer
hybridization site and a PCR primer complementary to the third primer hybridization site or with a PCR primer complementary
to the second and third primer hybridization site; and

(vi) performing a polymerase chain reaction to amplify the nucleic acid template or a fragment thereof.
US Pat. No. 9,163,284

METHODS FOR IDENTIFYING A TARGET SITE OF A CAS9 NUCLEASE

President and Fellows of ...

1. A method for identifying a target site of an RNA-programmable nuclease, the method comprising
(a) providing an RNA-programmable nuclease that cuts a double-stranded nucleic acid target site, wherein cutting of the target
site results in cut nucleic acid strands comprising a 5? phosphate moiety;

(b) contacting the RNA-programmable nuclease of (a) with a library of candidate nucleic acid molecules, wherein each nucleic
acid molecule comprises a concatemer of a sequence comprising a candidate nuclease target site and a constant insert sequence
of at least 10 and not more than 70 nucleotides, under conditions suitable for the RNA-programmable nuclease to cut a candidate
nucleic acid molecule comprising a target site of the RNA-programmable nuclease; and

(c) identifying nuclease target sites cut by the RNA-programmable nuclease in (b) by direct sequencing of an intact nuclease
target site on the nucleic acid strand that was cut by the RNA-programmable nuclease in step (b), wherein the method does
not include computational reconstruction of nuclease target sites from cut half-sites.

US Pat. No. 9,131,687

ROSEOBACTICIDES AND USES THEREOF

PRESIDENT AND FELLOWS OF ...

1. The algicide formulation comprising a compound comprising the formula:

or a salt thereof, and an algicide, a herbicide, a bactericide or a fungicide,
wherein R1 is optionally substituted aryl, optionally substituted heteroaryl, optionally substituted phenyl or an optionally substitute
indole;

wherein R2 is OR7, SR7, SO2R7, or SSR7;

wherein R7 is H, methyl, ethyl, propyl, butyl, pentyl, hexyl, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted acyl, optionally substituted arylcarbonyl, optionally substituted aryl or formula
(I);

wherein m is 0, 1, 2, 3, or 4, and
wherein R3 is OR6, SR6, SSR6, halogen, CN, N(R6)2, NO2, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl;

wherein R6 is H, methyl, ethyl, propyl, butyl, pentyl, hexyl, optionally substituted alkyl, optionally substituted alkenyl, optionally
substituted alkynyl, optionally substituted acyl;

and wherein X is O, S, NR6.

US Pat. No. 9,952,096

ULTRA-THIN OPTICAL COATINGS AND DEVICES AND METHODS OF USING ULTRA-THIN OPTICAL COATINGS

PRESIDENT AND FELLOWS OF ...

1. A device with a working wavelength of ?, comprising:a reflector that is reflective at the working wavelength of ?, the reflector comprising a substrate having an unpolished surface and a reflective layer disposed over the unpolished surface of the substrate; and
a dielectric layer disposed over the reflector, wherein a refractive index of the dielectric layer is n at ?, an extinction coefficient of the dielectric layer is k at ?, k is equal to or greater than 0.5 in at least one state of the dielectric layer, and a thickness h of the dielectric layer is less than ?/4n such that the reflector and the dielectric layer form a resonator at ?.

US Pat. No. 9,686,867

FOLDABLE MACHINES

Massachussetts Institute ...

1. A method for fabricating a machine, the method comprising:
defining a set of machine parameters which define a machine for accomplishing a task, the machine parameters comprising a
folding pattern for forming the machine from a foldable substrate and circuit locations for placement of circuits on the substrate;

storing the set of machine parameters as a machine model in a computer storage;
applying the folding pattern to at least one surface of the substrate;
forming one or more conductive signal paths directly on at least one surface of the substrate, wherein forming one or more
conductive signal paths includes etching a circuit pattern on a conductive foil layer disposed on the at least one surface
of the substrate such that the conductive signal paths correspond to metallic traces disposed on the at least one surface
of the substrate and such that at least one of the conductive signal paths is formed across a fold of the folding pattern;

disposing circuit components directly on one or more surfaces of said substrate such that the circuit components are directly
electrically coupled to the conductive signal paths thereby forming one or more electrical circuits; and

folding the substrate according to the folding pattern, such that the substrate is folded into the machine wherein the machine
is provided having moving parts controlled by the electrical circuits and wherein folding the substrate includes folding the
at least one conductive signal path that crosses the fold.

US Pat. No. 9,260,753

SINGLE CELL NUCLEIC ACID DETECTION AND ANALYSIS

President and Fellows of ...

1. A method of determining copy number of nucleic acid molecule in a sample including a plurality of nucleic acid molecules
comprising:
attaching a unique barcode sequence to substantially each of the plurality of nucleic acid molecules in the sample to produce
a plurality of differently barcoded nucleic acid molecules,

amplifying the plurality of differently barcoded nucleic acid molecules in the sample to produce amplicons of the plurality
of differently barcoded nucleic acid molecules,

sequencing each amplicon to identify an associated nucleic acid sequence and an associated barcode sequence,
selecting a first target nucleic acid sequence and determining the number of unique associated barcode sequence for the first
target nucleic acid sequence, wherein the number of unique associated barcode sequences is the copy number of the first target
nucleic acid sequence.

US Pat. No. 9,068,006

GLYCATED CD59 PEPTIDES, THEIR PREPARATION, AND USES THEREOF

President and Fellows of ...

1. A peptide comprising a segment of CD59 of the formula:

or a protected form thereof, wherein each sidechain of each amino acid residue of said peptide optionally comprises an
group;
wherein
each R1 is independently hydrogen or Pg1 and wherein two Pg1 groups may combine to form a heterocyclic ring;

each X is O or NH;
each R6 is independently hydrogen or Pg2;

each R7 is independently hydrogen; Pg2, or Pg3;

each R8 is independently hydrogen or Pg4;

each Pg1 is an independently selected hydroxyl protecting group;

each Pg2 is an independently selected amino protecting group;

each Pg3 is an independently selected carboxyl protecting group; and

each Pg4 is an independently selected thiol protecting group.

US Pat. No. 10,010,594

METHODS AND COMPOSITIONS FOR TRANSGENE EXPRESSION IN A HERPESVIRUS VECTOR SYSTEM

UNIVERSITY OF MIAMI, Mia...

1. A replication-competent herpesvirus vector system comprising (a) a polynucleotide encoding a trans-inducer polypeptide that enhances expression of a herpesvirus late gene, and (b) a polynucleotide comprising a heterologous recombinant transgene of interest operably linked to a promoter, wherein said heterologous recombinant transgene of interest comprises a codon usage signature of the herpesvirus late gene.

US Pat. No. 9,443,205

ENHANCING DIAGNOSIS OF DISORDER THROUGH ARTIFICIAL INTELLIGENCE AND MOBILE HEALTH TECHNOLOGIES WITHOUT COMPROMISING ACCURACY

PRESIDENT AND FELLOWS OF ...

1. A computer implemented method of generating a diagnostic tool for diagnosis of a behavioral disorder of a subject by applying
machine learning to a diagnostic instrument for diagnosis of the behavioral disorder, wherein the diagnostic instrument comprises
a set of diagnostic questions and corresponding selectable answers, the computer implemented method comprising:
on a computer system having one or more processors and a memory storing one or more computer programs for execution by the
one or more processors, the one or more computer programs including instructions for:

receiving as input diagnostic outcomes and selected answers to the set of diagnostic questions of a plurality of subjects
previously evaluated for the behavioral disorder;

analyzing the diagnostic outcomes and the selected answers of the plurality of previously evaluated subjects with the machine
learning to construct a behavioral classifier to distinguish among previously evaluated subjects with different diagnostic
outcomes, the behavioral classifier comprising a subset of the set of diagnostic questions and corresponding selectable answers
from the diagnostic instrument;

determining the accuracy of the behavioral classifier comprising the subset of diagnostic questions and corresponding selectable
answers, by testing the behavioral classifier against an independent source of clinical data, wherein the behavioral classifier
comprising the subset of diagnostic questions and corresponding selectable answers has an accuracy over 90%;

generating the diagnostic tool for diagnosis of the behavioral disorder, wherein the diagnostic tool comprises the behavioral
classifier and the subset of diagnostic questions and corresponding selectable answers having the accuracy greater than 90%;
and

configuring a computing device accessible by a user to display the subset of diagnostic questions and corresponding selectable
answers to the user, to collect user selected answers for the subset of diagnostic questions, and to provide the user selected
answers as input into the behavioral classifier in order to diagnose the behavioral disorder of the subject with the behavioral
classifier.

US Pat. No. 9,228,822

NON-DIFFERENTIAL ELASTOMER CURVATURE SENSOR

President and Fellows of ...

1. A method of determining a measure of curvature applied to a curvature sensor, the curvature sensor including a conductive
fluid filling a channel embedded in the curvature sensor, the method comprising:
measuring a change in curvature along a bending plane of the curvature sensor by:
measuring at a first time the electric resistance of the conductive fluid;
measuring at a second time the electric resistance of the conductive fluid;
determining a relative change in the electrical resistance of the channel; and
determining the change in curvature as a function of the change in electrical resistance.
US Pat. No. 10,130,661

DEVICES FOR WOUND HEALING

President and Fellows of ...

16. The method of claim 11, wherein the population of fibroblasts comprises an allogeneic or xenogeneic fibroblast.

US Pat. No. 9,683,197

DYNAMIC AND SWITCHABLE SLIPPERY SURFACES

President and Fellows of ...

1. A method of altering one or more characteristics of a structure, the method comprising:
providing a structure comprising a roughened surface which is optionally functionalized to immobilize a lubricating liquid,
wherein the lubricating liquid wets and adheres to the roughened surface to form a layer having a smooth planar upper surface
over the roughened surface to obtain a first characteristic of the structure; and

applying or removing a first stimulus to the structure, wherein the application or removal of the first stimulus exposes a
portion of the underlying substrate or disrupts the smoothness and/or planarity of the upper surface of the lubricating liquid
layer to obtain a second characteristic of the structure;

wherein:
the first stimulus comprises heat and wherein the heat stimulus causes temperature-induced melting of a solid lubricant or
a change in viscosity of the lubricant; and

the first stimulus is selected to alter the shape, volume or configuration of the underlying substrate, such that the underlying
substrate is exposed when the underlying substrate is in an expanded or contracted state.

US Pat. No. 9,322,006

EVALUATION AND IMPROVEMENT OF NUCLEASE CLEAVAGE SPECIFICITY

President and Fellows of ...

1. A method comprising
(a) providing a dimeric nuclease that cuts one or more double-stranded target sites of a double-stranded nucleic acid and
creates a 5? overhang on the double-stranded nucleic acid, wherein the dimeric nuclease comprises two nuclease monomers, and
wherein each of the target sites comprises

(i) a left-half site, wherein the left-half site comprises a nucleic acid sequence that is bound by one monomer of the dimeric
nuclease;

(ii) a right-half site, wherein the right-half site comprises a nucleic acid sequence that is bound by other monomer of the
dimeric nuclease; and

(iii) a spacer sequence between the left-half site and the right-half site;
wherein the left-half site, the spacer sequence, and right-half site forms a 5?-[the left-half site]-[the spacer sequence]-[the
right-half site]-3? (LSR) structure, and the cleavage site of the dimeric nuclease is located within the spacer sequence;

(b) contacting the dimeric nuclease with a library of candidate nucleic acid molecules, wherein each of the candidate nucleic
acid molecules comprises a concatemer containing multiple copies of identical DNA sequences, a plurality of the target sites
and multiple constant insert sequences, each of the constant insert sequences is located between two target sites of the plurality
of the target sites, and each of the multiple copies of the identical DNA sequences comprises a target site of the plurality
of the target sites and a constant insert sequence of the multiple constant insert sequences, under conditions suitable for
the dimeric nuclease to cut a candidate nucleic acid molecule of the library of candidate nucleic acid molecules; thereby
generating one or more candidate nucleic acid molecules cut once, twice and multiple times by the dimeric nuclease, wherein
the candidate nucleic acid molecules cut twice by the dimeric nuclease comprise a 5? overhang and the constant insert sequence
flanked by the left half-site and a part of the spacer sequence from one of the plurality of the target sites, and flanked
by the right half-site and a part of the spacer sequence from another of the plurality of the target sites,

(c) filling in the 5? overhang of each of the one or more candidate nucleic acid molecules cut twice by the dimeric nuclease,
thereby creating one or more candidate nucleic acid molecules with blunt ends; and

(d) identifying the one or more target sites of the one or more candidate nucleic acid molecules cut twice by the dimeric
nuclease by determining the sequence of the one or more candidate nucleic acid molecules with blunt ends created in step (c).

US Pat. No. 9,770,471

CONVERSION OF SOMATIC CELLS INTO FUNCTIONAL SPINAL MOTOR NEURONS, AND METHODS AND USES THEREOF

PRESIDENT AND FELLOWS OF ...

1. A method for producing a motor neuron from transdifferentiation of fibroblast, the method comprising increasing the protein
expression of at least four motor-neuron inducing (MN-inducing) factors in the fibroblast, wherein the four motor-neuron inducing
factors are Lhx3 and Ascl1 and two motor neuron inducing factors selected from the group consisting of: Brn2, Myt1l, Isl1,
Hb9, Ngn2 or NeuroD, and wherein the motor neuron exhibits at least two characteristics selected from:
(i) the expression of at least two genes selected from the group consisting of: ?2-tubulins, Map2, synapsins, synaptophysin,
synaptotagmins, NeuroD, Isl1, cholineacetyltransferase (ChAT), or

(ii) functional characteristic of any of: ability to fire action potentials, produce an outward current in response to glycine,
GABA or kainate, or produce an inward current in response to glutamate, and

wherein the fibroblast does not become a motor neuron progenitor prior to transdifferentiating into a motor neuron.

US Pat. No. 9,634,454

LASER ILLUMINATION SYSTEMS AND METHODS FOR DUAL-EXCITATION WAVELENGTH NON-LINEAR OPTICAL MICROSCOPY AND MICRO-SPECTROSCOPY SYSTEMS

PRESIDENT AND FELLOWS OF ...

1. An illumination system for providing dual excitation wavelength illumination for non-linear optical microscopy and micro-spectroscopy,
said illumination system comprising:
a laser system for providing a first train of pulses at a center optical frequency ?1;

a frequency converting system for providing at least a second train of pulses at a center optical frequency ?2 and a third train of pulses at a center optical frequency ?3, where ?2 is different from ?1 and ?3 responsive to the first train of pulses;

an amplifier system for amplifying the second train of pulses to provide an amplified second train of pulses; and
an adjustment means for adjusting a time delay between the amplified second train of pulses and the third train of pulses
for the dual-excitation wavelength illumination.

US Pat. No. 9,519,705

METHOD AND APPARATUS FOR SELECTING CLUSTERINGS TO CLASSIFY A DATA SET

PRESIDENT AND FELLOWS OF ...

1. A method for selecting clusterings to classify a data set, the method implemented in a data processor having a memory and
a display and comprising:
a) using the data processor to create a lower dimensional space of all possible clusterings and storing the space in the memory,
each clustering being associated with an allocation of objects to be clustered and corresponding to a point in the lower dimensional
space;

b) using the data processor to sample the stored lower dimensional space based on a number of objects in the data set;
c) using the data processor to build partitions based on the samples that tessellate the lower-dimensional space of all possible
clusterings, the clusterings being tessellated based on similarities among the objects in the associated allocations;

d) using the data processor to select partitions and determine remaining point locations in the lower dimensional space;
e) using the data processor to project the points of the lower dimensional space to a two dimensional array of points; and
f) displaying, on the display, points in the two-dimensional array.
US Pat. No. 9,498,538

TRANSLOCATION OF NON-NATURAL CHEMICAL ENTITIES THROUGH ANTHRAX PROTECTIVE ANTIGEN PORE

Massachusetts Institute o...

1. A method of disrupting a molecular interaction in a living cell, comprising
contacting the living cell with a pore forming protein and a fusion molecule comprising a pore specific delivery protein linked
to a reagent, wherein the reagent is delivered to the cytosol of the living cell in an effective amount for disrupting a molecular
interaction in the living cell.

US Pat. No. 9,452,992

SMALL MOLECULE INHIBITORS OF EBOLA AND LASSA FEVER VIRUSES

President and Fellows of ...

1. A compound represented by formula I:

or a pharmaceutically acceptable salt, solvate, hydrate, enantiomer or stereoisomer thereof; wherein, independently for each
occurrence,

W is

R is

X is

n is 1 or 2;
A is adamant-1-yl, 3-alkyladamant-1-yl, 5-alkyladamant-1-yl or 3,5-dialkyladamantyl;

R2 is hydrogen, halo, alkyl or haloalkyl;

R3 is hydrogen, halo, alkyl, haloalkyl, alkenyl, or aryl;

R4 is hydrogen or alkyl;

R5 is hydrogen, alkyl, haloalkyl or alkyl substituted with one or two substituents independently selected from halo, cyano, haloalkyl,
aralkyl, hydroxy, alkyloxy, carboxy, alkyloxycarbonyl, haloalkyloxycarbonyl, carbocyclyloxycarbonyl, aryloxycarbonyl, carbocyclylalkyloxycarbonyl,
and aralkyloxycarbonyl; and

R6 is phenyl or pyridinyl, optionally substituted with one, two, three or four substituents selected from hydroxy, alkyloxy,
tert-butyldimethylsilyloxy, methylenedioxy, ethylenedioxy, propylenedioxy, butylenedioxy, alkyl, haloalkyl, trifluoromethyl,
fluoro, chloro, bromo, iodo, cyano, nitro, acetylamino, carboxy and alkyloxycarbonyl;

provided the compound is not

US Pat. No. 9,445,769

METHOD AND APPARATUS FOR DETECTING DISEASE REGRESSION THROUGH NETWORK-BASED GAIT ANALYSIS

President and Fellows of ...

1. A method for determining a regression of a medical condition, the method comprising:
receiving, by a processor deployed in a communication network, characteristics of motion information, wherein the characteristics
of motion information is based upon gait information;

comparing, by the processor, the characteristics of motion information over a time period to a profile of the medical condition,
wherein the profile of the medical condition comprises a plurality of signatures associated with different stages of the medical
condition, wherein each of the plurality of signatures comprises a hidden markov model, wherein each of the plurality of signatures
is a signature of a mode of motion that is associated with one of the different stages of the medical condition;

determining, by the processor, a potential presence of the regression of the medical condition when the characteristics of
motion information matches at least two of the plurality of signatures; and

transmitting, by the processor, a notification of the potential presence of the regression of the medical condition.

US Pat. No. 9,343,206

ELECTRICALLY-DRIVEN PHASE TRANSITIONS IN FUNCTIONAL OXIDE HETEROSTRUCTURES

PRESIDENT AND FELLOWS OF ...

1. A system comprising:
a layer of a first functional material deposited on a component of the system, wherein the first functional material undergoes
a phase transition at a first critical voltage;

an insulating layer deposited upon the layer of first functional material; and
a layer of a second functional material deposited on the insulating layer, wherein the second functional material undergoes
a phase transition at a second critical voltage;

wherein the insulating layer is configured to induce a stress on the layer of the first functional material so as to change
the first critical voltage, so that the resistance of the system is tunable so as to allow the system to undergo multi-stage
electrical switching of resistive states.

US Pat. No. 10,065,989

MOLECULAR SLEDS AND USES THEREOF

The Broad Institute Inc.,...

1. A non-naturally occurring or engineered composition comprising:(a) a molecular sled comprising a core sequence of amino acids, wherein the core sequence is KKRRRCX? (SEQ ID NO: 2), or KKRRRCF (SEQ ID NO: 4), wherein X? is any amino acid;
(b) one or more linkers comprising one or more amino acids; and
(c) a molecular cargo linked to the one or more linkers; and
wherein the core sequence of amino acids KKRRRCX? (SEQ ID NO: 2), or KKRRRCF (SEQ ID NO: 4) is capable of sliding on a negatively charged polymer track.

US Pat. No. 9,598,690

METHOD FOR FORMING NANOPARTICLES HAVING PREDETERMINED SHAPES

President and Fellows of ...

1. A method comprising:
growing a nanoparticle from a nanoparticle precursor inside a nucleic acid container by applying a stimulus to the nanoparticle
precursor positioned inside of the nucleic acid container, wherein the nucleic acid container is a template for formation
of the nanoparticle, wherein the nanoparticle has a different shape than the nanoparticle precursor, wherein the nanoparticle
comprises at least one surface portion having a shape that is complementary to a shape of an inner surface portion of the
nucleic acid container having a predetermined three-dimensional structure at the sub-nanometer level, and wherein the nanoparticle
and the nucleic acid container have a three-dimensional shape that includes at least 4 different sides.

US Pat. No. 9,273,084

MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF

President and Fellows of ...

1. A compound of Formula (I):

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, isomer, enantiomer, diastereomer, or polymorph thereof;
wherein:
G is a group of Formula (a), (b), or (c):

wherein a is 3, 4, or 5;

wherein:
X1, X2, X3, X4, X5, X6, and X7 are each independently hydrogen or halogen;

d is an integer between 1 and 25, inclusive; and
e is an integer of between 2 and 25, inclusive;
provided that at least one of X1, X2, X3, X4, X5, X6, and X7 is halogen; and

the sum of d and e is greater than 16;or
wherein:
Y is —O—, —S—, —NRY—, or an optionally substituted methylene group, wherein RY is hydrogen, optionally substituted aliphatic, or an amino protecting group;

each instance of Rc is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted
carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORe, —SRe, —NHRe, or —N(Re)2, wherein each instance of Re is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted
carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two
Re groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;

each instance of Rd is independently —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted
carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORf, —SRf, —NHRf, or —N(Rf)2, wherein each instance of Rf is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted
carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl, or two
Rf groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;

Rz is hydrogen, —F, —Br, —I, —Cl, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted
carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, optionally substituted heteroaryl, —ORg, —SRg, —NHRg, or —N(Rg)2, wherein each instance of Rg is independently hydrogen, optionally substituted aliphatic, optionally substituted heteroaliphatic, optionally substituted
carbocycyl, optionally substituted heterocycyl, optionally substituted aryl, or optionally substituted heteroaryl or two Rg groups are joined to form a 5- to 6-membered optionally substituted heterocycyl or optionally substituted heteroaryl ring;

each instance of n is, independently, 0, 1, 2, 3, or 4;
each instance of m is, independently, 0, 1, 2, 3, or 4; and
x is 1, 2, 3, 4, 5, or 6;
Rxx is hydrogen, a hydroxyl protecting group, or a group of Formula:


R12 is hydrogen, a hydroxyl protecting group, or the group (D):


wherein R13, R14, R15, R16, and R17 are each independently hydrogen or a hydroxyl protecting group;

R1, R2, R3, and R4 are each independently hydrogen or an amino protecting group;

R5 is hydrogen, an amino protecting group, or the group (A):


R6, R7, R8, R9, R10, and R11 are each independently hydrogen or a hydroxyl protecting group; and

Ra and Rb are each independently hydrogen or a hydroxyl protecting group.

US Pat. No. 9,136,146

FEMTOSECOND LASER-INDUCED FORMATION OF SUBMICROMETER SPIKES ON A SEMICONDUCTOR SUBSTRATE

President And Fellows Of ...

1. A system for fabricating a radiation-absorbing semiconductor substrate, comprising:
a laser radiation system for generating laser pulses,
a vacuum chamber including a window for entry of said laser pulses into the chamber,
a translation stage disposed in said vacuum chamber and configured for supporting a sample, said stage allowing moving the
sample relative to the laser pulses for exposing different portions of a surface of the sample to said laser pulses,

a liquid cell coupled to the stage so as to provide contact between a liquid contained therein and said surface of the sample,
wherein the vacuum chamber is configured to allow pumping out air bubbles in said liquid.

US Pat. No. 9,121,306

SLIPPERY SURFACES WITH HIGH PRESSURE STABILITY, OPTICAL TRANSPARENCY, AND SELF-HEALING CHARACTERISTICS

President and Fellows of ...

1. An article having a repellant surface, the article comprising:
a substrate comprising a plurality of raised structures, wherein the raised structures have a predetermined roughness, have
feature sizes ranging from about 10 nm to about 100 ?m, and are substantially free of three-dimensionally interconnected pores,

a lubricating liquid that has a chemical affinity to the substrate, as determined by an equilibrium contact angle of less
than 90°, to wet spontaneously the substrate,

the lubricating liquid wetting and adhering to the plurality of raised structures to provide a stabilized liquid at a thickness
sufficient to form a liquid overlayer above the plurality of raised structures, and

wherein the predetermined roughness and the feature sizes are effective to substantially stably immobilize the lubricating
liquid between, on and over the plurality of raised structures, without dewetting from the substrate, to form a repellant
surface.

US Pat. No. 9,051,564

COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS

President and Fellows of ...

1. A method of determining whether a member of a library contains or encodes an immunogenic polypeptide, wherein said library
comprises at least 20 discrete members in defined locations and said members each comprise a cell or virus comprising a pre-determined
open reading frame from the genome of a pathogenic organism, said pre-predetermined open reading frame operably linked to
a promoter,
said method comprising:
(a) individually contacting a member of said library with a second cell capable of (i) endocytosing said cell or said virus
and (ii) displaying a polypeptide encoded by said pre-determined open reading frame on its surface through the major histocompatibility
complex (MHC) class I pathway;

(b) individually contacting said second cell from step (a) with a cytotoxic T lymphocyte (CTL) cell derived from a mammal
previously infected with said pathogenic organism; and

(c) detecting whether said CTL cell is activated, wherein activation of said CTL cell indicates that said member of said library
contains said pre-determined open reading frame which encodes at least a portion of said immunogenic polypeptide.

US Pat. No. 10,073,035

SUB-DIFFRACTION LIMIT IMAGE RESOLUTION AND OTHER IMAGING TECHNIQUES

President and Fellows of ...

24. A method, comprising:applying activation light for activating a part of a plurality of photoswitchable entities into a state able to emit light;
applying excitation light for exciting at least a part of the activated entities;
detecting at least a part of light emitted from the excited entities; and
calculating positional information of at least a part of the plurality of entities by using information contained in the detected light, correcting the positional information by using a fiduciary marker and movements of the fiduciary marker.

US Pat. No. 9,944,705

ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF

Novartis AG, Basel (CH) ...

1. An antibody molecule capable of binding to human Programmed Death-Ligand 1 (PD-L1), comprising:(a) a heavy chain variable region (VH) comprising a VHCDR1 amino acid sequence of SEQ ID NO: 4; a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a light chain variable region (VL) comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14;
(b) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 1; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 9, a VLCDR2 amino acid sequence of SEQ ID NO: 10, and a VLCDR3 amino acid sequence of SEQ ID NO: 11;
(c) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 195; a VHCDR2 amino acid sequence of SEQ ID NO: 5, and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 12, a VLCDR2 amino acid sequence of SEQ ID NO: 13, and a VLCDR3 amino acid sequence of SEQ ID NO: 14; or
(d) a VH comprising a VHCDR1 amino acid sequence of SEQ ID NO: 195; a VHCDR2 amino acid sequence of SEQ ID NO: 2; and a VHCDR3 amino acid sequence of SEQ ID NO: 3; and a VL comprising a VLCDR1 amino acid sequence of SEQ ID NO: 9, a VLCDR2 amino acid sequence of SEQ ID NO: 10, and a VLCDR3 amino acid sequence of SEQ ID NO: 11.

US Pat. No. 9,880,356

APPARATUS FOR COUPLING TO HIGH-INDEX MICRO-RESONATORS WITH TAPERED OPTICAL FIBERS

PRESIDENT AND FELLOWS OF ...

1. A device comprising:
an optical fiber, the optical fiber having a central axis, a tapered portion, and an untapered portion, the tapered portion
configured to expose an evanescent field; and

an elongated waveguide optically coupled to the optical fiber along the tapered portion and disposed parallel to the central
axis of the optical fiber, the elongated waveguide having a substantially triangular cross section in a plane perpendicular
to the central axis of the optical fiber.

US Pat. No. 9,682,168

D, L-CYCLIC PEPTIDE NANOTUBE REINFORCING AGENTS

President and Fellows of ...

1. A nanotube-reinforced polymer composite, comprising a plurality of nanotubes within a polymer matrix,
wherein each nanotube comprises a self-assembling, non-covalently bonded plurality of D,L cyclic peptide molecules,
wherein each D,L cyclic peptide molecule is a cyclic oligomer of about 6-12 ?-amino acid residues, wherein each amino acid
residue bears an ?-hydrogen atom and a non-hydrogen ?-substituent,

wherein the amino acid residues of each cyclic peptide molecule have alternating absolute configurations,
and wherein the amino acid residues of each D,L cyclic peptide molecule comprise a first type of amino acid of a first absolute
configuration, and a second type of amino acid of an opposite absolute configuration.